<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24204984</article-id><article-id pub-id-type="pmc">3810136</article-id><article-id pub-id-type="publisher-id">PONE-D-13-23948</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0077823</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Essential Amino Acid Enriched High-Protein Enteral Nutrition Modulates Insulin-Like Growth Factor-1 System Function in a Rat Model of Trauma-Hemorrhagic Shock</article-title><alt-title alt-title-type="running-head">Nutrient Mediate IGF-1 System Function</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Xianfeng</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xinying</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qiurong</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jieshou</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1">
<addr-line>Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Vinciguerra</surname><given-names>Manlio</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1">
<addr-line>University College London, United Kingdom</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>wxinying@263.net</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: XX XW. Performed the experiments: XX. Analyzed the data: XX. Contributed reagents/materials/analysis tools: XW QL NL JL. Wrote the paper: XX.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2013</year></pub-date><volume>8</volume><issue>10</issue><elocation-id>e77823</elocation-id><history><date date-type="received"><day>10</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>4</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 Xia et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Xia et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="4006" xml_f="4016" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4027" xml_f="4531" txt_i="22" txt_f="526">Nutrition support for critically ill patients supplemented with additional modular protein may promote skeletal muscle protein anabolism in addition to counteracting acute nitrogen loss. The present study was designed to investigate whether the essential amino acid (EAA) enriched high-protein enteral nutrition (EN) modulates the insulin-like growth factor-1 (IGF-1) system and activates the mammalian target of rapamycin (mTOR) anabolic signaling pathway in a trauma-hemorrhagic shock (T-HS) rat model.</offsets></p></sec><sec><title><offsets xml_i="4553" xml_f="4583" txt_i="528" txt_f="558">Methodology/Principal Findings</offsets></title><p><offsets xml_i="4594" xml_f="5731" txt_i="559" txt_f="1696">Male Sprague-Dawley rats (n = 90, 278.18±0.94 g) were randomly assigned to 5 groups: (1) normal control, (2) pair-fed, (3) T-HS, (4) T-HS and standard EN, and (5) T-HS and EAA enriched high-protein EN. Six animals from each group were harvested on days 2, 4, and 6 for serum, gastrocnemius, soleus, and extensor digitorum longus sample collection. T-HS significantly reduced muscle mass. Nutrition support maintained muscle mass, especially the EAA enriched high-protein EN. Meanwhile, a pronounced derangement in IGF-1-IGFBPs axis as well as impaired mTOR transduction was observed in the T-HS group. Compared with animals receiving standard EN, those receiving EAA enriched high-protein EN presented 18% higher serum free IGF-1 levels following 3 days of nutrition support and 22% higher after 5 days. These changes were consistent with the concomitant elevation in serum insulin and reduction in corticosterone levels. In addition, phosphorylations of downstream anabolic signaling effectors - including protein kinase B, mTOR, and ribosomal protein S6 kinase1 - increased significantly in rats receiving EAA enriched high-protein EN.</offsets></p></sec><sec><title><offsets xml_i="5753" xml_f="5776" txt_i="1698" txt_f="1721">Conclusion/Significance</offsets></title><p><offsets xml_i="5787" xml_f="6017" txt_i="1722" txt_f="1952">Our findings firstly demonstrate the beneficial effect of EAA enriched high-protein EN on the metabolic modulation of skeletal muscle protein anabolism by regulating the IGF-1 system and downstream anabolic signaling transduction.</offsets></p></sec></abstract><funding-group><funding-statement>The authors’ research project is sponsored by the National Natural Science Foundation in China (81070282) and the Natural Science Foundation in Jiangsu Province (BK2010460). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="12"></page-count></counts></article-meta></front><body><sec id="s1"><title><offsets xml_i="6509" xml_f="6521" txt_i="1961" txt_f="1973">Introduction</offsets></title><p><offsets xml_i="6532" xml_f="6715" txt_i="1974" txt_f="2157">Increased nitrogen loss and skeletal muscle wasting are metabolic features in patients under catabolic stress. Nearly 20% of total body protein can be lost in critically ill patients </offsets><xref rid="pone.0077823-Biolo1" ref-type="bibr"><offsets xml_i="6763" xml_f="6766" txt_i="2157" txt_f="2160">[1]</offsets></xref><offsets xml_i="6773" xml_f="6925" txt_i="2160" txt_f="2312">, and this severely negative nitrogen balance can adversely affect morbidity and mortality. The erosion of lean body mass is undoubtedly multifactorial </offsets><xref rid="pone.0077823-Skipworth1" ref-type="bibr"><offsets xml_i="6977" xml_f="6980" txt_i="2312" txt_f="2315">[2]</offsets></xref><offsets xml_i="6987" xml_f="6989" txt_i="2315" txt_f="2317">, </offsets><xref rid="pone.0077823-Klaude1" ref-type="bibr"><offsets xml_i="7038" xml_f="7041" txt_i="2317" txt_f="2320">[3]</offsets></xref><offsets xml_i="7048" xml_f="7174" txt_i="2320" txt_f="2446">; but it is in part attributed to the reduction in circulating insulin-like growth factor-1 (IGF-1) levels or IGF-1 signaling </offsets><xref rid="pone.0077823-Okamoto1" ref-type="bibr"><offsets xml_i="7224" xml_f="7227" txt_i="2446" txt_f="2449">[4]</offsets></xref><offsets xml_i="7234" xml_f="7236" txt_i="2449" txt_f="2451">, </offsets><xref rid="pone.0077823-Elijah1" ref-type="bibr"><offsets xml_i="7285" xml_f="7288" txt_i="2451" txt_f="2454">[5]</offsets></xref><offsets xml_i="7295" xml_f="7538" txt_i="2454" txt_f="2697">. In normal physiological state, IGF-1 bonds to the type-1 cell-surface receptor and then exerts an anabolic effect by activating the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB/Akt)-mammalian target of rapamycin (mTOR) pathway </offsets><xref rid="pone.0077823-Janssen1" ref-type="bibr"><offsets xml_i="7588" xml_f="7591" txt_i="2697" txt_f="2700">[6]</offsets></xref><offsets xml_i="7598" xml_f="7600" txt_i="2700" txt_f="2702">, </offsets><xref rid="pone.0077823-Clemmons1" ref-type="bibr"><offsets xml_i="7651" xml_f="7654" txt_i="2702" txt_f="2705">[7]</offsets></xref><offsets xml_i="7661" xml_f="7926" txt_i="2705" txt_f="2970">. Stimulation of mTOR complex1 (mTORC1) contributes to the phosphorylations of two key downstream effectors, eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and p70 ribosomal protein S6 kinase1 (p70S6K1), which then induce protein translation initiation </offsets><xref rid="pone.0077823-Howell1" ref-type="bibr"><offsets xml_i="7975" xml_f="7978" txt_i="2970" txt_f="2973">[8]</offsets></xref><offsets xml_i="7985" xml_f="7987" txt_i="2973" txt_f="2975">, </offsets><xref rid="pone.0077823-Ma1" ref-type="bibr"><offsets xml_i="8032" xml_f="8035" txt_i="2975" txt_f="2978">[9]</offsets></xref><offsets xml_i="8042" xml_f="8244" txt_i="2978" txt_f="3180">. The sustained decrease in circulating IGF-1 levels under catabolic states is thus believed to be responsible, at least in part, for the impaired IGF-1 bioactivity and damaged muscle protein anabolism.</offsets></p><p><offsets xml_i="8251" xml_f="8500" txt_i="3181" txt_f="3430">IGF-1 circulating in the peripheral vasculature bonds to specific binding proteins. Approximate 95% of circulating IGF-1 forms a ternary complex consisting with insulin-like growth factor binding protein 3 (IGFBP-3) and an acid-labile subunit (ALS) </offsets><xref rid="pone.0077823-Kelley1" ref-type="bibr"><offsets xml_i="8549" xml_f="8553" txt_i="3430" txt_f="3434">[10]</offsets></xref><offsets xml_i="8560" xml_f="8705" txt_i="3434" txt_f="3579">. This ternary complex regulates the biologic effect of IGF-1, functioning as a storage reservoir of IGF-1 in plasma and extending its half-life.</offsets></p><p><offsets xml_i="8712" xml_f="9010" txt_i="3580" txt_f="3878">Endogenous IGF-1 synthesis is quite sensitive to nutrient availability. In previous work, a 60% reduction in plasma IGF-1 concentrations as well as 8% decrease in gastrocnemius mass was observed in rats receiving a protein-free diet, while recovering to normal after standard casein diet refeeding </offsets><xref rid="pone.0077823-Gomes1" ref-type="bibr"><offsets xml_i="9058" xml_f="9062" txt_i="3878" txt_f="3882">[11]</offsets></xref><offsets xml_i="9069" xml_f="9163" txt_i="3882" txt_f="3976">. Dietary protein intake is also associated with IGF-1 status and whole-body nitrogen economy </offsets><xref rid="pone.0077823-SanchezGomez1" ref-type="bibr"><offsets xml_i="9218" xml_f="9222" txt_i="3976" txt_f="3980">[12]</offsets></xref><offsets xml_i="9229" xml_f="9389" txt_i="3980" txt_f="4140">. In patients with recent hip fracture, a significant elevation of serum IGF-1 levels was observed as early as 7 days after 20 g/(kg·d) protein supplementation </offsets><xref rid="pone.0077823-Chevalley1" ref-type="bibr"><offsets xml_i="9441" xml_f="9445" txt_i="4140" txt_f="4144">[13]</offsets></xref><offsets xml_i="9452" xml_f="9624" txt_i="4144" txt_f="4316">. Meanwhile, clinical study revealed that amino acid infusion during anesthesia could attenuate the decrease in IGF-1 levels and maintain glucose homeostasis after surgery </offsets><xref rid="pone.0077823-Wallin1" ref-type="bibr"><offsets xml_i="9673" xml_f="9677" txt_i="4316" txt_f="4320">[14]</offsets></xref><offsets xml_i="9684" xml_f="9896" txt_i="4320" txt_f="4532">. These results collectively indicated that elevated serum IGF-1 levels appeared to be associated with the response to protein or amino acid supplementation during fasting or stress period. In addition, Takenaka </offsets><italic><offsets xml_i="9904" xml_f="9910" txt_i="4532" txt_f="4538">et al.</offsets></italic><offsets xml_i="9919" xml_f="9920" txt_i="4538" txt_f="4539">
</offsets><xref rid="pone.0077823-Takenaka1" ref-type="bibr"><offsets xml_i="9971" xml_f="9975" txt_i="4539" txt_f="4543">[15]</offsets></xref><offsets xml_i="9982" xml_f="10402" txt_i="4543" txt_f="4963"> reported that dietary restriction of signal essential amino acid (EAA) decreased IGF-1 production, suggesting that adequate EAA in diet might be required for the IGF-1 synthesis. A recent study regarding acute regulation of the IGF-1 system by macronutrients further demonstrated that EAA/carbohydrate mixture ingestion following high-intensity exercise promoted a significant increase in circulating free IGF-1 levels </offsets><xref rid="pone.0077823-Foster1" ref-type="bibr"><offsets xml_i="10451" xml_f="10455" txt_i="4963" txt_f="4967">[16]</offsets></xref><offsets xml_i="10462" xml_f="10463" txt_i="4967" txt_f="4968">.</offsets></p><p><offsets xml_i="10470" xml_f="10756" txt_i="4969" txt_f="5255">The essential role of nutrition support for critically ill patients is to promote protein anabolism and protect the lean body mass and function. Historically, providing equivalent amounts of protein or amino acids in nutrition support attempted to counteract the dramatic nitrogen loss </offsets><xref rid="pone.0077823-McClave1" ref-type="bibr"><offsets xml_i="10806" xml_f="10810" txt_i="5255" txt_f="5259">[17]</offsets></xref><offsets xml_i="10817" xml_f="11007" txt_i="5259" txt_f="5449">. However, it remains to be elucidated whether adequate protein intake modulates the stress response and muscle protein anabolism during critical illness through the IGF-1 system regulation.</offsets></p><p><offsets xml_i="11014" xml_f="11505" txt_i="5450" txt_f="5941">Therefore, the purpose of the present study was to investigate the role of long-term enteral nutrition (EN), in particular EAA enriched high-protein EN, upon the regulation of IGF-1 system function and downstream mTOR-related signaling transduction in a Sprague-Dawley (SD) rat model of trauma-hemorrhagic shock (T-HS). Serum levels of insulin and corticosterone were also measured, since both factors were implicated in the regulation of IGF-1 by their respective roles in IGFBP regulation </offsets><xref rid="pone.0077823-Wojnar1" ref-type="bibr"><offsets xml_i="11554" xml_f="11558" txt_i="5941" txt_f="5945">[18]</offsets></xref><offsets xml_i="11565" xml_f="11566" txt_i="5945" txt_f="5946">.</offsets></p></sec><sec sec-type="materials|methods" id="s2"><title><offsets xml_i="11625" xml_f="11646" txt_i="5948" txt_f="5969">Materials and Methods</offsets></title><sec id="s2a"><title><offsets xml_i="11675" xml_f="11682" txt_i="5970" txt_f="5977">Animals</offsets></title><p><offsets xml_i="11693" xml_f="11981" txt_i="5978" txt_f="6266">Male SD rats weighted 278.18±0.94 g (Medical Experiment Animal Center of Jinling Hospital, Nanjing, China) were housed in a temperature (25∼28°C) and light (12∶12-hour light-dark cycle) controlled environment for 1 week prior to the experiment. Water and standard chow diet were provided </offsets><italic><offsets xml_i="11989" xml_f="11999" txt_i="6266" txt_f="6276">ad libitum</offsets></italic><offsets xml_i="12008" xml_f="12290" txt_i="6276" txt_f="6558">. All procedures were carried out in accordance with the “Guide for the Care and Use of Laboratory Animals” published by the National Institutes of Health (NIH publication 86-23 revised 1985) and following protocols approved by the Animal Care and Use Committee of Jinling Hospital.</offsets></p></sec><sec id="s2b"><title><offsets xml_i="12321" xml_f="12365" txt_i="6560" txt_f="6604">Surgical Procedure and Experimental Design (</offsets><xref ref-type="fig" rid="pone-0077823-g001"><offsets xml_i="12410" xml_f="12418" txt_i="6604" txt_f="6612">Figure 1</offsets></xref><offsets xml_i="12425" xml_f="12426" txt_i="6612" txt_f="6613">)</offsets></title><p><offsets xml_i="12437" xml_f="13670" txt_i="6614" txt_f="7847">Following the acclimatization period, rats were fasted overnight (Day-1). All surgeries were performed using sterile technique. At day 0, rats were anesthetized by intraperitoneal injection of ketamine (100 mg/kg body weight (BW)) and placed on a temperature-controlled heating pad. A midline laparotomy (5 cm) was made to insert a catheter (ID 0.8 mm, OD 1.2 mm) into the anterior wall of the stomach followed by suturing to the stomach wall and exteriorizing through the anterolateral abdominal wall. The catheter was then subcutaneously tunneled to the shoulder region, and connected through a customized rotating swivel to a 50 mL syringe pump (Research Center for Analytical Instrument, Zhejiang University, China). An additional groin incision was made. The left femoral artery was catheterized for bleeding, monitoring mean arterial pressure (MAP), and fluid resuscitation through a three-way microvalve. Rats were bled to a target MAP of 30∼35 mmHg within 15 minutes and maintained for 45 minutes. Blood pressure was recorded in 5-minute intervals. At the end of hemorrhagic shock period, rats were resuscitated by infusing their shed blood and lactated Ringer’s solution in a 1∶2 ratio. All rats were allowed food and water </offsets><italic><offsets xml_i="13678" xml_f="13688" txt_i="7847" txt_f="7857">ad libitum</offsets></italic><offsets xml_i="13697" xml_f="13708" txt_i="7857" txt_f="7868"> overnight.</offsets></p><fig id="pone-0077823-g001" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="13809" xml_f="13842" txt_i="7869" txt_f="7902">10.1371/journal.pone.0077823.g001</offsets></object-id><label><offsets xml_i="13861" xml_f="13869" txt_i="7902" txt_f="7910">Figure 1</offsets></label><caption><title><offsets xml_i="13893" xml_f="13913" txt_i="7910" txt_f="7930">Experimental design.</offsets></title><p><offsets xml_i="13924" xml_f="14351" txt_i="7931" txt_f="8358">This study includes five groups. After undergoing the trauma-hemorrhagic shock (T-HS) operation, rats received either standard enteral nutrition (EN) (T-HS/SE), essential amino acid (EAA) enriched high-protein EN (T-HS/EAA), or a continue infusion of isotonic saline but on normal chow diet (T-HS/Ctr). Food intake in a pair-fed group (PF) was restricted to the T-HS/Ctr group. A normal control group (NC) without T-HS and fed </offsets><italic><offsets xml_i="14359" xml_f="14369" txt_i="8358" txt_f="8368">ad libitum</offsets></italic><offsets xml_i="14378" xml_f="14482" txt_i="8368" txt_f="8472"> chow was also included. Six individuals in each group were harvested on days 2, 4, and 6, respectively.</offsets></p></caption><graphic xlink:href="pone.0077823.g001"></graphic></fig><p><offsets xml_i="14555" xml_f="15037" txt_i="8473" txt_f="8955">Animals were randomized to 5 groups. At T-HS 3 groups, rats received either standard EN (T-HS/SE, n = 18), EAA enriched high-protein EN (T-HS/EAA, n = 18), or a continue infusion of isotonic saline but on normal chow diet (T-HS/Ctr, n = 18). One group that was pair-fed (PF, n = 18) with the T-HS/Ctr group was set to control for the influence of reduced food intake post-operatively. Rats in the normal control group (NC, n = 18) were under no treatment and fed standard chow diet </offsets><italic><offsets xml_i="15045" xml_f="15055" txt_i="8955" txt_f="8965">ad libitum</offsets></italic><offsets xml_i="15064" xml_f="15086" txt_i="8965" txt_f="8987"> throughout the study.</offsets></p></sec><sec id="s2c"><title><offsets xml_i="15117" xml_f="15134" txt_i="8989" txt_f="9006">Nutrition Program</offsets></title><p><offsets xml_i="15145" xml_f="15625" txt_i="9007" txt_f="9487">Following overnight recovery (Day 1), chow diet was removed from rats in the T-HS/SE and T-HS/EAA groups. A continuous EN infusion was started and provided for the subsequent 5 days, providing a non-protein calorie of 250 kcal/(kg BW·d). The T-HS/SE rats received ENSURE® (Lot# 10127NR, Abbott Laboratories B.v., Zwolle, Netherlands) (64.38 g/(kg BW·d), providing 1.65 g N/(kg BW·d)) as the standard enteral formula, in which the ratio of non-protein calorie to nitrogen is 152∶1 </offsets><bold><offsets xml_i="15631" xml_f="15632" txt_i="9487" txt_f="9488">(</offsets></bold><offsets xml_i="15639" xml_f="15640" txt_i="9488" txt_f="9489">
</offsets><xref ref-type="table" rid="pone-0077823-t001"><offsets xml_i="15687" xml_f="15688" txt_i="9489" txt_f="9490">
</offsets><bold><offsets xml_i="15694" xml_f="15701" txt_i="9490" txt_f="9497">Table 1</offsets></bold><offsets xml_i="15708" xml_f="15709" txt_i="9497" txt_f="9498">
</offsets></xref><offsets xml_i="15716" xml_f="15717" txt_i="9498" txt_f="9499">
</offsets><bold><offsets xml_i="15723" xml_f="15724" txt_i="9499" txt_f="9500">)</offsets></bold><offsets xml_i="15731" xml_f="16021" txt_i="9500" txt_f="9790">. Additional nitrogen supplementation in the T-HS/EAA group was provided by leucine enriched EAA solution containing 0.849 g N/(kg BW·d) based on the ENSURE® diet. Therefore, the ratio of non-protein calorie to nitrogen decreases to 100∶1. The composition of the EAA mixture is provided in </offsets><xref ref-type="table" rid="pone-0077823-t002"><offsets xml_i="16068" xml_f="16069" txt_i="9790" txt_f="9791">
</offsets><bold><offsets xml_i="16075" xml_f="16082" txt_i="9791" txt_f="9798">Table 2</offsets></bold><offsets xml_i="16089" xml_f="16090" txt_i="9798" txt_f="9799">
</offsets></xref><offsets xml_i="16097" xml_f="16144" txt_i="9799" txt_f="9846">, with minor modifications to previous studies </offsets><xref rid="pone.0077823-Katsanos1" ref-type="bibr"><offsets xml_i="16195" xml_f="16199" txt_i="9846" txt_f="9850">[19]</offsets></xref><offsets xml_i="16206" xml_f="16208" txt_i="9850" txt_f="9852">, </offsets><xref rid="pone.0077823-Fujita1" ref-type="bibr"><offsets xml_i="16257" xml_f="16261" txt_i="9852" txt_f="9856">[20]</offsets></xref><offsets xml_i="16268" xml_f="16415" txt_i="9856" txt_f="10003">. Half of the estimated requirement based upon individual BW was administrated on the first day and the full requirement was provided subsequently.</offsets></p><table-wrap id="pone-0077823-t001" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="16523" xml_f="16556" txt_i="10004" txt_f="10037">10.1371/journal.pone.0077823.t001</offsets></object-id><label><offsets xml_i="16575" xml_f="16582" txt_i="10037" txt_f="10044">Table 1</offsets></label><caption><title><offsets xml_i="16606" xml_f="16654" txt_i="10044" txt_f="10092">Nutrition composition of standard diet: ENSURE®.</offsets></title></caption><alternatives><graphic id="pone-0077823-t001-1" xlink:href="pone.0077823.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16948" xml_f="16969" txt_i="10093" txt_f="10114">Nutrition Composition</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17015" xml_f="17029" txt_i="10115" txt_f="10129">/100 g formula</offsets></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17099" xml_f="17107" txt_i="10130" txt_f="10138">Energy, </offsets><italic><offsets xml_i="17115" xml_f="17119" txt_i="10138" txt_f="10142">kcal</offsets></italic><offsets xml_i="17128" xml_f="17129" txt_i="10142" txt_f="10143">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17175" xml_f="17178" txt_i="10144" txt_f="10147">450</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17233" xml_f="17242" txt_i="10148" txt_f="10157">Protein, </offsets><italic><offsets xml_i="17250" xml_f="17251" txt_i="10157" txt_f="10158">g</offsets></italic><offsets xml_i="17260" xml_f="17261" txt_i="10158" txt_f="10159">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17307" xml_f="17311" txt_i="10160" txt_f="10164">15.9</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17366" xml_f="17371" txt_i="10165" txt_f="10170">Fat, </offsets><italic><offsets xml_i="17379" xml_f="17380" txt_i="10170" txt_f="10171">g</offsets></italic><offsets xml_i="17389" xml_f="17390" txt_i="10171" txt_f="10172">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17436" xml_f="17440" txt_i="10173" txt_f="10177">15.9</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17495" xml_f="17510" txt_i="10178" txt_f="10193">Linoleic acid, </offsets><italic><offsets xml_i="17518" xml_f="17519" txt_i="10193" txt_f="10194">g</offsets></italic><offsets xml_i="17528" xml_f="17529" txt_i="10194" txt_f="10195">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17575" xml_f="17578" txt_i="10196" txt_f="10199">8.7</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17633" xml_f="17647" txt_i="10200" txt_f="10214">Carbohydrate, </offsets><italic><offsets xml_i="17655" xml_f="17656" txt_i="10214" txt_f="10215">g</offsets></italic><offsets xml_i="17665" xml_f="17666" txt_i="10215" txt_f="10216">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17712" xml_f="17716" txt_i="10217" txt_f="10221">60.7</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17771" xml_f="17781" txt_i="10222" txt_f="10232">Moisture, </offsets><italic><offsets xml_i="17789" xml_f="17790" txt_i="10232" txt_f="10233">g</offsets></italic><offsets xml_i="17799" xml_f="17800" txt_i="10233" txt_f="10234">
</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="17846" xml_f="17847" txt_i="10235" txt_f="10236">5</offsets></td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0077823-t002" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="18005" xml_f="18038" txt_i="10237" txt_f="10270">10.1371/journal.pone.0077823.t002</offsets></object-id><label><offsets xml_i="18057" xml_f="18064" txt_i="10270" txt_f="10277">Table 2</offsets></label><caption><title><offsets xml_i="18088" xml_f="18140" txt_i="10277" txt_f="10329">The composition of the essential amino acid mixture.</offsets></title></caption><alternatives><graphic id="pone-0077823-t002-2" xlink:href="pone.0077823.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18434" xml_f="18455" txt_i="10330" txt_f="10351">Essential amino acids</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18501" xml_f="18515" txt_i="10352" txt_f="10366">Percentage (%)</offsets></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18585" xml_f="18591" txt_i="10367" txt_f="10373">Lysine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18637" xml_f="18640" txt_i="10374" txt_f="10377">13%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18695" xml_f="18705" txt_i="10378" txt_f="10388">Tryptophan</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18751" xml_f="18753" txt_i="10389" txt_f="10391">8%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18808" xml_f="18821" txt_i="10392" txt_f="10405">Phenylalanine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18867" xml_f="18869" txt_i="10406" txt_f="10408">8%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18924" xml_f="18931" txt_i="10409" txt_f="10416">Leucine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18977" xml_f="18980" txt_i="10417" txt_f="10420">38%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19035" xml_f="19045" txt_i="10421" txt_f="10431">Isoleucine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19091" xml_f="19093" txt_i="10432" txt_f="10434">9%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19148" xml_f="19154" txt_i="10435" txt_f="10441">Valine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19200" xml_f="19203" txt_i="10442" txt_f="10445">11%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19258" xml_f="19267" txt_i="10446" txt_f="10455">Threonine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19313" xml_f="19316" txt_i="10456" txt_f="10459">10%</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19371" xml_f="19381" txt_i="10460" txt_f="10470">Methionine</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19427" xml_f="19429" txt_i="10471" txt_f="10473">3%</offsets></td></tr></tbody></table></alternatives></table-wrap><p><offsets xml_i="19486" xml_f="19738" txt_i="10474" txt_f="10726">In the T-HS/Ctr group, rats received saline at a constant rate of 0.3 mL/(100 g BW·h) through the enteral routine and had free access to chow diet. Food intake in PF rats was restricted to the T-HS/Ctr group. All rats were allowed free access to water.</offsets></p><p><offsets xml_i="19745" xml_f="19912" txt_i="10727" txt_f="10894">BW and the amount of EN solution infused were recorded daily. Frequency of diarrhea was also observed to evaluate the tolerance of EN in the T-HS/SE and T-HS/EAA rats.</offsets></p></sec><sec id="s2d"><title><offsets xml_i="19943" xml_f="19960" txt_i="10896" txt_f="10913">Sample Collection</offsets></title><p><offsets xml_i="19971" xml_f="20302" txt_i="10914" txt_f="11245">Rats (n = 6) were euthanized from each group on days 2, 4, and 6, respectively. EN was stopped 1 hour before sacrifice in the T-HS/SE and T-HS/EAA groups. After anesthesia, blood was collected by cardiac puncture. Serum was isolated by centrifuge at 4000 rpm at 4°C for 10 minutes and then kept at −80°C until further measurements.</offsets></p><p><offsets xml_i="20309" xml_f="20539" txt_i="11246" txt_f="11476">The gastrocnemius, soleus, and extensor digitorum longus (EDL) of the right leg were dissected out, weighted, wrapped, and then snap frozen in liquid nitrogen within 3 minutes. All samples were then stored at −80°C until analysis.</offsets></p></sec><sec id="s2e"><title><offsets xml_i="20570" xml_f="20702" txt_i="11478" txt_f="11610">Determination of Serum Free IGF-1, IGFBP-1, IGFBP-3, Insulin, and Corticosterone Levels by Enzyme-linked Immunosorbent Assay (ELISA)</offsets></title><p><offsets xml_i="20713" xml_f="20969" txt_i="11611" txt_f="11863">In contrast to measuring total serum IGF-1 levels, we utilized a commercial IGF-1 ELISA kit from R&amp;D Inc. (Minneapolis, MN, USA) to determine the free serum IGF-1 concentrations, which represent the “bioavailable” portion of the circulating IGF-1 pool </offsets><xref rid="pone.0077823-Foster1" ref-type="bibr"><offsets xml_i="21018" xml_f="21022" txt_i="11863" txt_f="11867">[16]</offsets></xref><offsets xml_i="21029" xml_f="21227" txt_i="11867" txt_f="12061">. Serum concentrations of IGFBP-1, IGFBP-3, insulin, and corticosterone were also determined by ELISA kits (R&amp;D Systems, Minneapolis, MN, USA) in accordance with the manufacturer’s instructions.</offsets></p></sec><sec id="s2f"><title><offsets xml_i="21258" xml_f="21270" txt_i="12063" txt_f="12075">Western Blot</offsets></title><p><offsets xml_i="21281" xml_f="21368" txt_i="12076" txt_f="12163">Muscle preparation and western blotting analysis were performed as previously detailed </offsets><xref rid="pone.0077823-Wang1" ref-type="bibr"><offsets xml_i="21415" xml_f="21419" txt_i="12163" txt_f="12167">[21]</offsets></xref><offsets xml_i="21426" xml_f="21619" txt_i="12167" txt_f="12360">. Briefly, ∼ 80 mg of frozen muscle sample was homogenized in RIPA lysis buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing 200 mM NaF, 1 mM Na</offsets><sub><offsets xml_i="21624" xml_f="21625" txt_i="12360" txt_f="12361">3</offsets></sub><offsets xml_i="21631" xml_f="21633" txt_i="12361" txt_f="12363">VO</offsets><sub><offsets xml_i="21638" xml_f="21639" txt_i="12363" txt_f="12364">4</offsets></sub><offsets xml_i="21645" xml_f="22140" txt_i="12364" txt_f="12859">, 25 mM β-glycerophosphate, 1 mM PMSF, and 1% protein inhibitor Cocktail (Sigma-Aldrich Inc., St. Louis, MO, USA ) for 30 minutes on ice. The lysate was then centrifuged at 12,000 g at 4°C for 8 minutes, and the supernatant was collected. Total protein concentration was determined using the BCA assay (Sangon Biotech Co., Shanghai, China). The supernatant was diluted (4∶1) in a 5× loading buffer (Beyotime Institute of Biotechnology Co., Nantong, China) and then boiled at 100°C for 5 minutes.</offsets></p><p><offsets xml_i="22147" xml_f="23169" txt_i="12860" txt_f="13882">Equal amounts of total protein (75 ug) were separated by 8% or 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) determined by the size of target protein and then transferred to polyvinylidene difluoride membrane (Millipore Co., Billerica, MA, USA). Blots were blocked in 5% BSA for 1 hour at room temperature and incubated in specific primary antibodies overnight at 4°C. Blots were then washed in TBST (Tris-buffered saline and 0.05% Tween-20) three times followed by incubation with secondary antibody for 2 hours at room temperature. The protein bands were visualized by a chemiluminescence detection system (Pierce Biotechnology Inc., Rockford, IL, USA) with exposure to Kodak XAR film (Eastman Kodak). Band density was analyzed using Quantity One 4.6.2 software (BioRad). Specific total protein was re-probed after stripping the phospho-primary and secondary antibody. Phosphorylation data are described relative to the total protein expression after normalization by internal loading control.</offsets></p></sec><sec id="s2g"><title><offsets xml_i="23200" xml_f="23210" txt_i="13884" txt_f="13894">Antibodies</offsets></title><p><offsets xml_i="23221" xml_f="23677" txt_i="13895" txt_f="14347">Antibodies that detected α-tublin (1∶1000), phospho-mTOR (Ser2448; 1∶500), S6K1 (1∶1000), phospho-S6K1 (Thr389; 1∶500), and phospho-Akt (Ser473; 1∶1000) were from Cell Signaling Technology (Beverly, MA, USA). Akt (1∶1000) and mTOR (1∶1000) antibodies were from Abcam (Cambridge, UK). Anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (1∶3000) was from Kirkegaard &amp; Perry Laboratories (KPL) Biotechnology Inc. (Gaithersburg, ML, USA).</offsets></p></sec><sec id="s2h"><title><offsets xml_i="23708" xml_f="23805" txt_i="14349" txt_f="14446">Determination of Serum Amino Acid Concentrations by High-performance Liquid Chromatography (HPLC)</offsets></title><p><offsets xml_i="23816" xml_f="24051" txt_i="14447" txt_f="14682">Serum amino acid concentrations were assayed by a Waters Aliance 2695 HPLC system (Waters, MA, USA) after pre-column derivatization with phenylisothicyanate (PITC) (Thermo Scientific (Pierce), Rockford, IL, USA) by our previous method </offsets><xref rid="pone.0077823-Luo1" ref-type="bibr"><offsets xml_i="24097" xml_f="24101" txt_i="14682" txt_f="14686">[22]</offsets></xref><offsets xml_i="24108" xml_f="24217" txt_i="14686" txt_f="14795">. Data were calculated on the basis of external amino acid standard (Sigma-Aldrich Inc., St. Louis, MO, USA).</offsets></p></sec><sec id="s2i"><title><offsets xml_i="24248" xml_f="24268" txt_i="14797" txt_f="14817">Statistical Analysis</offsets></title><p><offsets xml_i="24279" xml_f="24674" txt_i="14818" txt_f="15213">Results are expressed as mean ± SE. Repeated-measures ANOVA was used to characterize dietary intake and BW gain during the 6-day recovery period. For other purposes, statistical evaluation among groups was performed by one-way ANOVA followed by LSD post-hoc analysis, using SPSS software package (SPPS Inc., Chicago, IL, USA). In the case of heterogeneous variances, we used Dunnet’s T3 test. A </offsets><italic><offsets xml_i="24682" xml_f="24683" txt_i="15213" txt_f="15214">p</offsets></italic><offsets xml_i="24692" xml_f="24735" txt_i="15214" txt_f="15254"> value &lt;0.05 was considered significant.</offsets></p></sec></sec><sec id="s3"><title><offsets xml_i="24771" xml_f="24778" txt_i="15257" txt_f="15264">Results</offsets></title><sec id="s3a"><title><offsets xml_i="24807" xml_f="24840" txt_i="15265" txt_f="15298">1. Growth Assessment during Study</offsets></title><p><offsets xml_i="24851" xml_f="24966" txt_i="15299" txt_f="15414">The average incidence of diarrhea was 0.44/day on the first day following T-HS, and gradually disappeared at day 3 </offsets><bold><offsets xml_i="24972" xml_f="24973" txt_i="15414" txt_f="15415">(</offsets></bold><offsets xml_i="24980" xml_f="24981" txt_i="15415" txt_f="15416">
</offsets><xref ref-type="fig" rid="pone-0077823-g002"><offsets xml_i="25026" xml_f="25027" txt_i="15416" txt_f="15417">
</offsets><bold><offsets xml_i="25033" xml_f="25042" txt_i="15417" txt_f="15426">Figure 2A</offsets></bold><offsets xml_i="25049" xml_f="25050" txt_i="15426" txt_f="15427">
</offsets></xref><offsets xml_i="25057" xml_f="25058" txt_i="15427" txt_f="15428">
</offsets><bold><offsets xml_i="25064" xml_f="25065" txt_i="15428" txt_f="15429">)</offsets></bold><offsets xml_i="25072" xml_f="25255" txt_i="15429" txt_f="15612">. Early EN failed to increase the incidence of diarrhea, indicating that rats in the T-HS/SE and T-HS/EAA groups tolerated the nutrition support. After T-HS, rats consumed less chow (</offsets><italic><offsets xml_i="25263" xml_f="25264" txt_i="15612" txt_f="15613">p</offsets></italic><offsets xml_i="25273" xml_f="25395" txt_i="15613" txt_f="15732">&lt;0.05) for 4 days but achieved normal by day 5, when the food intake did not differ between the T-HS/Ctr and NC groups </offsets><bold><offsets xml_i="25401" xml_f="25402" txt_i="15732" txt_f="15733">(</offsets></bold><offsets xml_i="25409" xml_f="25410" txt_i="15733" txt_f="15734">
</offsets><xref ref-type="fig" rid="pone-0077823-g002"><offsets xml_i="25455" xml_f="25456" txt_i="15734" txt_f="15735">
</offsets><bold><offsets xml_i="25462" xml_f="25471" txt_i="15735" txt_f="15744">Figure 2B</offsets></bold><offsets xml_i="25478" xml_f="25479" txt_i="15744" txt_f="15745">
</offsets></xref><offsets xml_i="25486" xml_f="25487" txt_i="15745" txt_f="15746">
</offsets><bold><offsets xml_i="25493" xml_f="25494" txt_i="15746" txt_f="15747">)</offsets></bold><offsets xml_i="25501" xml_f="25591" txt_i="15747" txt_f="15837">. The daily caloric intake of the T-HS/SE and T-HS/EAA groups is additionally provided in </offsets><xref ref-type="table" rid="pone-0077823-t003"><offsets xml_i="25638" xml_f="25639" txt_i="15837" txt_f="15838">
</offsets><bold><offsets xml_i="25645" xml_f="25652" txt_i="15838" txt_f="15845">Table 3</offsets></bold><offsets xml_i="25659" xml_f="25660" txt_i="15845" txt_f="15846">
</offsets></xref><offsets xml_i="25667" xml_f="25668" txt_i="15846" txt_f="15847">.</offsets></p><fig id="pone-0077823-g002" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="25769" xml_f="25802" txt_i="15848" txt_f="15881">10.1371/journal.pone.0077823.g002</offsets></object-id><label><offsets xml_i="25821" xml_f="25829" txt_i="15881" txt_f="15889">Figure 2</offsets></label><caption><title><offsets xml_i="25853" xml_f="25928" txt_i="15889" txt_f="15964">Observations of diarrhea and food intake in normal or T-HS injured animals.</offsets></title><p><offsets xml_i="25939" xml_f="26133" txt_i="15965" txt_f="16159">Diarrhea times (A) and food intake (B) in specific groups were recorded daily during study period. Values are presented as mean ± SE. Marker indicates a significant difference from NC group. *, </offsets><italic><offsets xml_i="26141" xml_f="26142" txt_i="16159" txt_f="16160">p</offsets></italic><offsets xml_i="26151" xml_f="26161" txt_i="16160" txt_f="16167">&lt;0.05; </offsets><sup><offsets xml_i="26166" xml_f="26167" txt_i="16167" txt_f="16168">#</offsets></sup><offsets xml_i="26173" xml_f="26175" txt_i="16168" txt_f="16170">, </offsets><italic><offsets xml_i="26183" xml_f="26184" txt_i="16170" txt_f="16171">p</offsets></italic><offsets xml_i="26193" xml_f="26234" txt_i="16171" txt_f="16209">&lt;0.01. T-HS, trauma-hemorrhagic shock.</offsets></p></caption><graphic xlink:href="pone.0077823.g002"></graphic></fig><table-wrap id="pone-0077823-t003" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="26408" xml_f="26441" txt_i="16210" txt_f="16243">10.1371/journal.pone.0077823.t003</offsets></object-id><label><offsets xml_i="26460" xml_f="26467" txt_i="16243" txt_f="16250">Table 3</offsets></label><caption><title><offsets xml_i="26491" xml_f="26545" txt_i="16250" txt_f="16304">Daily caloric intake in enterally fed rats (kcal/day).</offsets></title></caption><alternatives><graphic id="pone-0077823-t003-3" xlink:href="pone.0077823.t003"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col><col align="center" span="1"></col></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26979" xml_f="26985" txt_i="16305" txt_f="16311">Groups</offsets></td><td colspan="5" align="left" rowspan="1"><offsets xml_i="27031" xml_f="27041" txt_i="16312" txt_f="16322">Time point</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27142" xml_f="27147" txt_i="16324" txt_f="16329">Day 1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27193" xml_f="27198" txt_i="16330" txt_f="16335">Day 2</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27244" xml_f="27249" txt_i="16336" txt_f="16341">Day 3</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27295" xml_f="27300" txt_i="16342" txt_f="16347">Day 4</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27346" xml_f="27351" txt_i="16348" txt_f="16353">Day 5</offsets></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27421" xml_f="27428" txt_i="16354" txt_f="16361">T-HS/SE</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27474" xml_f="27484" txt_i="16362" txt_f="16372">33.03±0.18</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27530" xml_f="27540" txt_i="16373" txt_f="16383">65.21±0.98</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27586" xml_f="27596" txt_i="16384" txt_f="16394">67.79±0.66</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27642" xml_f="27652" txt_i="16395" txt_f="16405">69.25±0.98</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27698" xml_f="27708" txt_i="16406" txt_f="16416">69.69±0.87</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27763" xml_f="27771" txt_i="16417" txt_f="16425">T-HS/EAA</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27817" xml_f="27827" txt_i="16426" txt_f="16436">32.67±0.17</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27873" xml_f="27883" txt_i="16437" txt_f="16447">65.75±0.25</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27929" xml_f="27939" txt_i="16448" txt_f="16458">68.42±0.17</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="27985" xml_f="27995" txt_i="16459" txt_f="16469">69.25±0.25</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="28041" xml_f="28051" txt_i="16470" txt_f="16480">70.67±0.60</offsets></td></tr></tbody></table></alternatives></table-wrap><p><offsets xml_i="28108" xml_f="28268" txt_i="16481" txt_f="16641">Animals weighed an average of 278.18±0.94 g at the beginning of the study. BW was low in all T-HS injured rats throughout the study, but did increase with time </offsets><bold><offsets xml_i="28274" xml_f="28275" txt_i="16641" txt_f="16642">(</offsets></bold><offsets xml_i="28282" xml_f="28283" txt_i="16642" txt_f="16643">
</offsets><italic><offsets xml_i="28291" xml_f="28292" txt_i="16643" txt_f="16644">p</offsets></italic><offsets xml_i="28301" xml_f="28311" txt_i="16644" txt_f="16651">&lt;0.01, </offsets><xref ref-type="fig" rid="pone-0077823-g003"><offsets xml_i="28356" xml_f="28357" txt_i="16651" txt_f="16652">
</offsets><bold><offsets xml_i="28363" xml_f="28371" txt_i="16652" txt_f="16660">Figure 3</offsets></bold><offsets xml_i="28378" xml_f="28379" txt_i="16660" txt_f="16661">
</offsets></xref><offsets xml_i="28386" xml_f="28387" txt_i="16661" txt_f="16662">
</offsets><bold><offsets xml_i="28393" xml_f="28394" txt_i="16662" txt_f="16663">)</offsets></bold><offsets xml_i="28401" xml_f="28696" txt_i="16663" txt_f="16958">. Rats in the T-HS/Ctr group presented a relatively slow gain of BW during the recovery period. Nutrition support was thought to be beneficial for achieving weight gain, especially the EAA enriched high-protein EN, however no significant difference between groups was observed at any time point.</offsets></p><fig id="pone-0077823-g003" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="28797" xml_f="28830" txt_i="16959" txt_f="16992">10.1371/journal.pone.0077823.g003</offsets></object-id><label><offsets xml_i="28849" xml_f="28857" txt_i="16992" txt_f="17000">Figure 3</offsets></label><caption><title><offsets xml_i="28881" xml_f="28919" txt_i="17000" txt_f="17038">Changes in body weight of the animals.</offsets></title><p><offsets xml_i="28930" xml_f="29046" txt_i="17039" txt_f="17155">Values are presented as mean ± SE. Marker indicates a significant difference from other groups across study period. </offsets><sup><offsets xml_i="29051" xml_f="29052" txt_i="17155" txt_f="17156">#</offsets></sup><offsets xml_i="29058" xml_f="29060" txt_i="17156" txt_f="17158">, </offsets><italic><offsets xml_i="29068" xml_f="29069" txt_i="17158" txt_f="17159">p</offsets></italic><offsets xml_i="29078" xml_f="29087" txt_i="17159" txt_f="17165">&lt;0.01.</offsets></p></caption><graphic xlink:href="pone.0077823.g003"></graphic></fig><p><offsets xml_i="29160" xml_f="29228" txt_i="17166" txt_f="17234">T-HS induced significant reductions in gastrocnemius and EDL masses </offsets><bold><offsets xml_i="29234" xml_f="29235" txt_i="17234" txt_f="17235">(</offsets></bold><offsets xml_i="29242" xml_f="29243" txt_i="17235" txt_f="17236">
</offsets><xref ref-type="fig" rid="pone-0077823-g004"><offsets xml_i="29288" xml_f="29289" txt_i="17236" txt_f="17237">
</offsets><bold><offsets xml_i="29295" xml_f="29307" txt_i="17237" txt_f="17249">Figure 4A, B</offsets></bold><offsets xml_i="29314" xml_f="29315" txt_i="17249" txt_f="17250">
</offsets></xref><offsets xml_i="29322" xml_f="29323" txt_i="17250" txt_f="17251">
</offsets><bold><offsets xml_i="29329" xml_f="29330" txt_i="17251" txt_f="17252">)</offsets></bold><offsets xml_i="29337" xml_f="29466" txt_i="17252" txt_f="17381">. Gastrocnemius masses in the T-HS/SE and T-HS/EAA groups were significantly higher than the T-HS/Ctr group by 2 days post-T-HS (</offsets><italic><offsets xml_i="29474" xml_f="29475" txt_i="17381" txt_f="17382">p</offsets></italic><offsets xml_i="29484" xml_f="29709" txt_i="17382" txt_f="17604">&lt;0.01), and this trend continued throughout the remainder of the study. In addition, the T-HS/EAA group exhibited a significant increase in gastrocnemius mass compared with the T-HS/SE group on days 4 and 6, respectively (</offsets><italic><offsets xml_i="29717" xml_f="29718" txt_i="17604" txt_f="17605">p</offsets></italic><offsets xml_i="29727" xml_f="29898" txt_i="17605" txt_f="17773">&lt;0.01). However, both EN treatments had limited improvement in EDL mass maintenance. For soleus mass, a slight but without significant decrease was observed after T-HS </offsets><bold><offsets xml_i="29904" xml_f="29905" txt_i="17773" txt_f="17774">(</offsets></bold><offsets xml_i="29912" xml_f="29913" txt_i="17774" txt_f="17775">
</offsets><xref ref-type="fig" rid="pone-0077823-g004"><offsets xml_i="29958" xml_f="29959" txt_i="17775" txt_f="17776">
</offsets><bold><offsets xml_i="29965" xml_f="29974" txt_i="17776" txt_f="17785">Figure 4C</offsets></bold><offsets xml_i="29981" xml_f="29982" txt_i="17785" txt_f="17786">
</offsets></xref><offsets xml_i="29989" xml_f="29990" txt_i="17786" txt_f="17787">
</offsets><bold><offsets xml_i="29996" xml_f="29997" txt_i="17787" txt_f="17788">)</offsets></bold><offsets xml_i="30004" xml_f="30141" txt_i="17788" txt_f="17925">. EAA enriched high-protein EN caused a significant increase in soleus wet muscle mass by day 6, which was comparable with the NC group (</offsets><italic><offsets xml_i="30149" xml_f="30150" txt_i="17925" txt_f="17926">p</offsets></italic><offsets xml_i="30159" xml_f="30169" txt_i="17926" txt_f="17933">&lt;0.05).</offsets></p><fig id="pone-0077823-g004" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="30270" xml_f="30303" txt_i="17934" txt_f="17967">10.1371/journal.pone.0077823.g004</offsets></object-id><label><offsets xml_i="30322" xml_f="30330" txt_i="17967" txt_f="17975">Figure 4</offsets></label><caption><title><offsets xml_i="30354" xml_f="30389" txt_i="17975" txt_f="18010">Comparison of skeletal muscle mass.</offsets></title><p><offsets xml_i="30400" xml_f="30676" txt_i="18011" txt_f="18287">Wet masses of gastrocnemius (A), extensor digitorum longus (B), and soleus (C) in each group were measured following 2, 4, and 6 days of recovery from T-HS. Values are presented as mean ± SE. Groups with different letters at each time point indicate a significant difference (</offsets><italic><offsets xml_i="30684" xml_f="30685" txt_i="18287" txt_f="18288">p</offsets></italic><offsets xml_i="30694" xml_f="30736" txt_i="18288" txt_f="18327">&lt;0.05). T-HS, trauma-hemorrhagic shock.</offsets></p></caption><graphic xlink:href="pone.0077823.g004"></graphic></fig></sec><sec id="s3b"><title><offsets xml_i="30833" xml_f="30889" txt_i="18329" txt_f="18385">2. Serum Free IGF-1, IGFBP-3, and IGFBP-1 Concentrations</offsets></title><p><offsets xml_i="30900" xml_f="31020" txt_i="18386" txt_f="18506">Serum free IGF-1 concentrations in the PF, T-HS/Ctr, T-HS/SE, and T-HS/EAA groups were significantly decreased by day 2 </offsets><bold><offsets xml_i="31026" xml_f="31027" txt_i="18506" txt_f="18507">(</offsets></bold><offsets xml_i="31034" xml_f="31035" txt_i="18507" txt_f="18508">
</offsets><italic><offsets xml_i="31043" xml_f="31044" txt_i="18508" txt_f="18509">p</offsets></italic><offsets xml_i="31053" xml_f="31063" txt_i="18509" txt_f="18516">&lt;0.01, </offsets><xref ref-type="fig" rid="pone-0077823-g005"><offsets xml_i="31108" xml_f="31109" txt_i="18516" txt_f="18517">
</offsets><bold><offsets xml_i="31115" xml_f="31124" txt_i="18517" txt_f="18526">Figure 5A</offsets></bold><offsets xml_i="31131" xml_f="31132" txt_i="18526" txt_f="18527">
</offsets></xref><offsets xml_i="31139" xml_f="31140" txt_i="18527" txt_f="18528">
</offsets><bold><offsets xml_i="31146" xml_f="31147" txt_i="18528" txt_f="18529">)</offsets></bold><offsets xml_i="31154" xml_f="31359" txt_i="18529" txt_f="18734">. Following this time point, free IGF-1 concentrations increased gradually, but most slowly in the T-HS/Ctr group, which remained statistically lower than the other EN-treated groups (vs T-HS/SE at day 4, </offsets><italic><offsets xml_i="31367" xml_f="31368" txt_i="18734" txt_f="18735">p</offsets></italic><offsets xml_i="31377" xml_f="31409" txt_i="18735" txt_f="18764">&lt;0.05; vs T-HS/EAA at day 4, </offsets><italic><offsets xml_i="31417" xml_f="31418" txt_i="18764" txt_f="18765">p</offsets></italic><offsets xml_i="31427" xml_f="31470" txt_i="18765" txt_f="18805">&lt;0.01; vs T-HS/SE or T-HS/EAA at day 6, </offsets><italic><offsets xml_i="31478" xml_f="31479" txt_i="18805" txt_f="18806">p</offsets></italic><offsets xml_i="31488" xml_f="31643" txt_i="18806" txt_f="18958">&lt;0.01). In addition, lower free IGF-1 levels were measured in the T-HS/Ctr group than PF group at day 4 and it reached statistical difference by day 6 (</offsets><italic><offsets xml_i="31651" xml_f="31652" txt_i="18958" txt_f="18959">p</offsets></italic><offsets xml_i="31661" xml_f="31941" txt_i="18959" txt_f="19236">&lt;0.01), indicating that the depressed IGF-1 expression was sustained 6 days following T-HS after eliminating the interference of reduced food intake. Furthermore, free IGF-1 levels were 18% higher in the T-HS/EAA group than T-HS/SE group following 3 days of nutrition support (</offsets><italic><offsets xml_i="31949" xml_f="31950" txt_i="19236" txt_f="19237">p</offsets></italic><offsets xml_i="31959" xml_f="32035" txt_i="19237" txt_f="19310">&lt;0.05). And a greater magnitude was observed by day 6 (122%, vs T-HS/SE; </offsets><italic><offsets xml_i="32043" xml_f="32044" txt_i="19310" txt_f="19311">p</offsets></italic><offsets xml_i="32053" xml_f="32057" txt_i="19311" txt_f="19312">&lt;</offsets></p><fig id="pone-0077823-g005" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="32158" xml_f="32191" txt_i="19313" txt_f="19346">10.1371/journal.pone.0077823.g005</offsets></object-id><label><offsets xml_i="32210" xml_f="32218" txt_i="19346" txt_f="19354">Figure 5</offsets></label><caption><title><offsets xml_i="32242" xml_f="32289" txt_i="19354" txt_f="19401">ELISA analysis of IGF-1-IGFBPs axis expression.</offsets></title><p><offsets xml_i="32300" xml_f="32566" txt_i="19402" txt_f="19668">Serum concentrations of free IGF-1 (A), IGFBP-3 (B), and IGFBP-1 (C) in each group were measured following 2, 4, and 6 days of recovery from T-HS. Values are presented as mean ± SE. Groups with different letters at each time point indicate a significant difference (</offsets><italic><offsets xml_i="32574" xml_f="32575" txt_i="19668" txt_f="19669">p</offsets></italic><offsets xml_i="32584" xml_f="32626" txt_i="19669" txt_f="19708">&lt;0.05). T-HS, trauma-hemorrhagic shock.</offsets></p></caption><graphic xlink:href="pone.0077823.g005"></graphic></fig><p><offsets xml_i="32699" xml_f="32801" txt_i="19709" txt_f="19811">The pattern of serum IGFBP-3 concentrations between groups was similar to that observed in free IGF-1 </offsets><bold><offsets xml_i="32807" xml_f="32808" txt_i="19811" txt_f="19812">(</offsets></bold><offsets xml_i="32815" xml_f="32816" txt_i="19812" txt_f="19813">
</offsets><xref ref-type="fig" rid="pone-0077823-g005"><offsets xml_i="32861" xml_f="32862" txt_i="19813" txt_f="19814">
</offsets><bold><offsets xml_i="32868" xml_f="32877" txt_i="19814" txt_f="19823">Figure 5B</offsets></bold><offsets xml_i="32884" xml_f="32885" txt_i="19823" txt_f="19824">
</offsets></xref><offsets xml_i="32892" xml_f="32893" txt_i="19824" txt_f="19825">
</offsets><bold><offsets xml_i="32899" xml_f="32900" txt_i="19825" txt_f="19826">)</offsets></bold><offsets xml_i="32907" xml_f="33011" txt_i="19826" txt_f="19930">. In the T-HS/Ctr group, IGFBP-3 levels remained lower than the PF group on days 4 and 6, respectively (</offsets><italic><offsets xml_i="33019" xml_f="33020" txt_i="19930" txt_f="19931">p</offsets></italic><offsets xml_i="33029" xml_f="33153" txt_i="19931" txt_f="20052">&lt;0.01). Following enteral feeding, there was a significant elevation in IGFBP-3 levels compared with the T-HS/Ctr group (</offsets><italic><offsets xml_i="33161" xml_f="33162" txt_i="20052" txt_f="20053">p</offsets></italic><offsets xml_i="33171" xml_f="33358" txt_i="20053" txt_f="20237">&lt;0.01). Moreover, EAA enriched high-protein EN-fed rats exhibited a 170% and 140% increase in IGFBP-3 levels compared with animals receiving standard EN on days 4 and 6, respectively (</offsets><italic><offsets xml_i="33366" xml_f="33367" txt_i="20237" txt_f="20238">p</offsets></italic><offsets xml_i="33376" xml_f="33386" txt_i="20238" txt_f="20245">&lt;0.01).</offsets></p><p><offsets xml_i="33393" xml_f="33611" txt_i="20246" txt_f="20464">Serum IGFBP-1 levels in the NC group were markedly lower than the other groups at each time point, with the exception of day 6 when IGFBP-1 levels in the T-HS/EAA group decreased to levels comparable with the NC group </offsets><bold><offsets xml_i="33617" xml_f="33618" txt_i="20464" txt_f="20465">(</offsets></bold><offsets xml_i="33625" xml_f="33626" txt_i="20465" txt_f="20466">
</offsets><xref ref-type="fig" rid="pone-0077823-g005"><offsets xml_i="33671" xml_f="33672" txt_i="20466" txt_f="20467">
</offsets><bold><offsets xml_i="33678" xml_f="33687" txt_i="20467" txt_f="20476">Figure 5C</offsets></bold><offsets xml_i="33694" xml_f="33695" txt_i="20476" txt_f="20477">
</offsets></xref><offsets xml_i="33702" xml_f="33703" txt_i="20477" txt_f="20478">
</offsets><bold><offsets xml_i="33709" xml_f="33710" txt_i="20478" txt_f="20479">)</offsets></bold><offsets xml_i="33717" xml_f="33823" txt_i="20479" txt_f="20585">. T-HS increased IGFBP-1 concentrations in the T-HS/Ctr group by 46% compared with the PF group at day 2 (</offsets><italic><offsets xml_i="33831" xml_f="33832" txt_i="20585" txt_f="20586">p</offsets></italic><offsets xml_i="33841" xml_f="34073" txt_i="20586" txt_f="20815">&lt;0.01), and this trend was likely to continue throughout the study period. Although both groups of enterally fed rats exhibited significant decreases in IGFBP-1 levels compared with rats in the T-HS/Ctr group at each time point (</offsets><italic><offsets xml_i="34081" xml_f="34082" txt_i="20815" txt_f="20816">p</offsets></italic><offsets xml_i="34091" xml_f="34151" txt_i="20816" txt_f="20873">&lt;0.01), the reduction was greater in the T-HS/EAA group (</offsets><italic><offsets xml_i="34159" xml_f="34160" txt_i="20873" txt_f="20874">p</offsets></italic><offsets xml_i="34169" xml_f="34179" txt_i="20874" txt_f="20881">&lt;0.01).</offsets></p></sec><sec id="s3c"><title><offsets xml_i="34210" xml_f="34271" txt_i="20883" txt_f="20944">3. Serum Hormones (Insulin and Corticosterone) Concentrations</offsets></title><p><offsets xml_i="34282" xml_f="34399" txt_i="20945" txt_f="21062">Insulin levels in the T-HS/Ctr group were significantly decreased compared with the PF group at all the time points (</offsets><italic><offsets xml_i="34407" xml_f="34408" txt_i="21062" txt_f="21063">p</offsets></italic><offsets xml_i="34417" xml_f="34437" txt_i="21063" txt_f="21080">&lt;0.05, at day 2; </offsets><italic><offsets xml_i="34445" xml_f="34446" txt_i="21080" txt_f="21081">p</offsets></italic><offsets xml_i="34455" xml_f="34480" txt_i="21081" txt_f="21103">&lt;0.01, at day 4 or 6; </offsets><xref ref-type="fig" rid="pone-0077823-g006"><offsets xml_i="34525" xml_f="34526" txt_i="21103" txt_f="21104">
</offsets><bold><offsets xml_i="34532" xml_f="34541" txt_i="21104" txt_f="21113">Figure 6A</offsets></bold><offsets xml_i="34548" xml_f="34549" txt_i="21113" txt_f="21114">
</offsets></xref><offsets xml_i="34556" xml_f="34895" txt_i="21114" txt_f="21453">). Both enterally fed groups showed increase in insulin concentrations, but it failed to reach statistical difference compared with the T-HS/Ctr group at day 2. By day 4, standard and EAA enriched high-protein EN significantly increased insulin levels 1- and 1.3-fold, respectively, compared with the values detected in the T-HS/Ctr rats (</offsets><italic><offsets xml_i="34903" xml_f="34904" txt_i="21453" txt_f="21454">p</offsets></italic><offsets xml_i="34913" xml_f="35075" txt_i="21454" txt_f="21613">&lt;0.01). Moreover, a greater magnitude of feeding-induced hyperinsulinemia was observed in the T-HS/EAA group than T-HS/SE group on days 4 and 6, respectively (</offsets><italic><offsets xml_i="35083" xml_f="35084" txt_i="21613" txt_f="21614">p</offsets></italic><offsets xml_i="35093" xml_f="35103" txt_i="21614" txt_f="21621">&lt;0.01, </offsets><italic><offsets xml_i="35111" xml_f="35112" txt_i="21621" txt_f="21622">p</offsets></italic><offsets xml_i="35121" xml_f="35236" txt_i="21622" txt_f="21734">&lt;0.05). Regression analysis of insulin and IGF-1 further indicated a significantly positive liner relationship (</offsets><italic><offsets xml_i="35244" xml_f="35245" txt_i="21734" txt_f="21735">y</offsets></italic><offsets xml_i="35254" xml_f="35262" txt_i="21735" txt_f="21743"> = 0.038</offsets><italic><offsets xml_i="35270" xml_f="35271" txt_i="21743" txt_f="21744">x</offsets></italic><offsets xml_i="35280" xml_f="35287" txt_i="21744" txt_f="21751">−1.08; </offsets><italic><offsets xml_i="35295" xml_f="35296" txt_i="21751" txt_f="21752">R</offsets><sup><offsets xml_i="35301" xml_f="35302" txt_i="21752" txt_f="21753">2</offsets></sup></italic><offsets xml_i="35317" xml_f="35327" txt_i="21753" txt_f="21763"> = 0.483; </offsets><italic><offsets xml_i="35335" xml_f="35336" txt_i="21763" txt_f="21764">p</offsets></italic><offsets xml_i="35345" xml_f="35355" txt_i="21764" txt_f="21771">&lt;0.01).</offsets></p><fig id="pone-0077823-g006" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="35456" xml_f="35489" txt_i="21772" txt_f="21805">10.1371/journal.pone.0077823.g006</offsets></object-id><label><offsets xml_i="35508" xml_f="35516" txt_i="21805" txt_f="21813">Figure 6</offsets></label><caption><title><offsets xml_i="35540" xml_f="35588" txt_i="21813" txt_f="21861">ELISA analysis of serum hormones concentrations.</offsets></title><p><offsets xml_i="35599" xml_f="35855" txt_i="21862" txt_f="22118">Serum concentrations of insulin (A) and corticosterone (B) in each group were measured following 2, 4, and 6 days of recovery from T-HS. Values are presented as mean ± SE. Groups with different letters at each time point indicate a significant difference (</offsets><italic><offsets xml_i="35863" xml_f="35864" txt_i="22118" txt_f="22119">p</offsets></italic><offsets xml_i="35873" xml_f="35915" txt_i="22119" txt_f="22158">&lt;0.05). T-HS, trauma-hemorrhagic shock.</offsets></p></caption><graphic xlink:href="pone.0077823.g006"></graphic></fig><p><offsets xml_i="35988" xml_f="36084" txt_i="22159" txt_f="22255">Serum corticosterone concentrations in rats subjected to T-HS significantly increased by day 2 (</offsets><italic><offsets xml_i="36092" xml_f="36093" txt_i="22255" txt_f="22256">p</offsets></italic><offsets xml_i="36102" xml_f="36112" txt_i="22256" txt_f="22263">&lt;0.01, </offsets><xref ref-type="fig" rid="pone-0077823-g006"><offsets xml_i="36157" xml_f="36158" txt_i="22263" txt_f="22264">
</offsets><bold><offsets xml_i="36164" xml_f="36173" txt_i="22264" txt_f="22273">Figure 6B</offsets></bold><offsets xml_i="36180" xml_f="36181" txt_i="22273" txt_f="22274">
</offsets></xref><offsets xml_i="36188" xml_f="36377" txt_i="22274" txt_f="22463">). Concentrations in the T-HS/SE and T-HS/EAA groups gradually returned to normal as early as at day 4, whereas corticosterone levels in the T-HS/Ctr group remained statistically elevated (</offsets><italic><offsets xml_i="36385" xml_f="36386" txt_i="22463" txt_f="22464">p</offsets></italic><offsets xml_i="36395" xml_f="36547" txt_i="22464" txt_f="22613">&lt;0.01). Meanwhile, corticosterone levels in the T-HS/EAA group appeared lower than T-HS/SE group on days 4 and 6, but without statistical difference.</offsets></p></sec><sec id="s3d"><title><offsets xml_i="36578" xml_f="36595" txt_i="22615" txt_f="22632">4. Cell Signaling</offsets></title><p><offsets xml_i="36606" xml_f="36910" txt_i="22633" txt_f="22937">To further assess the signaling transduction associated with muscle protein synthesis, phosphorylations of several key proteins involved in mTOR signaling pathway were determined in gastrocnemius at day 6. After T-HS, phosphorylation of Akt at Ser473 in the T-HS/Ctr group was greatly suppressed (vs NC, </offsets><italic><offsets xml_i="36918" xml_f="36919" txt_i="22937" txt_f="22938">p</offsets></italic><offsets xml_i="36928" xml_f="36945" txt_i="22938" txt_f="22952">&lt;0.01; vs PF, </offsets><italic><offsets xml_i="36953" xml_f="36954" txt_i="22952" txt_f="22953">p</offsets></italic><offsets xml_i="36963" xml_f="36973" txt_i="22953" txt_f="22960">&lt;0.01; </offsets><xref ref-type="fig" rid="pone-0077823-g007"><offsets xml_i="37018" xml_f="37019" txt_i="22960" txt_f="22961">
</offsets><bold><offsets xml_i="37025" xml_f="37034" txt_i="22961" txt_f="22970">Figure 7A</offsets></bold><offsets xml_i="37041" xml_f="37042" txt_i="22970" txt_f="22971">
</offsets></xref><offsets xml_i="37049" xml_f="37170" txt_i="22971" txt_f="23092">). Phospho-Akt levels in the T-HS/EAA group, rather than T-HS/SE group, were significant higher than the T-HS/Ctr group (</offsets><italic><offsets xml_i="37178" xml_f="37179" txt_i="23092" txt_f="23093">p</offsets></italic><offsets xml_i="37188" xml_f="37415" txt_i="23093" txt_f="23317">&lt;0.01), coinciding with the fact that free IGF-1 levels peaked at day 6. Meanwhile, the phosphorylation of mTOR at Ser2448 in the T-HS/Ctr group decreased to 43.3% and 45.7% compared with the NC and PF groups, respectively (</offsets><italic><offsets xml_i="37423" xml_f="37424" txt_i="23317" txt_f="23318">p</offsets></italic><offsets xml_i="37433" xml_f="37443" txt_i="23318" txt_f="23325">&lt;0.01, </offsets><xref ref-type="fig" rid="pone-0077823-g007"><offsets xml_i="37488" xml_f="37489" txt_i="23325" txt_f="23326">
</offsets><bold><offsets xml_i="37495" xml_f="37504" txt_i="23326" txt_f="23335">Figure 7B</offsets></bold><offsets xml_i="37511" xml_f="37512" txt_i="23335" txt_f="23336">
</offsets></xref><offsets xml_i="37519" xml_f="37750" txt_i="23336" txt_f="23567">). A minor increase but without significance in phospho-mTOR levels was observed in rats receiving standard EN formula. However, in the T-HS/EAA group, mTOR phosphorylation at Ser2448 was significantly elevated (176%, vs T-HS/Ctr, </offsets><italic><offsets xml_i="37758" xml_f="37759" txt_i="23567" txt_f="23568">p</offsets></italic><offsets xml_i="37768" xml_f="37796" txt_i="23568" txt_f="23593">&lt;0.05; 166%, vs T-HS/SE, </offsets><italic><offsets xml_i="37804" xml_f="37805" txt_i="23593" txt_f="23594">p</offsets></italic><offsets xml_i="37814" xml_f="38035" txt_i="23594" txt_f="23812">&lt;0.05). As the important downstream effector of mTOR signaling, Thr389-phosphorylation of S6K1 was also measured. S6K1 phosphorylations in the PF and T-HS/Ctr groups were similar, but markedly lower than the NC group (</offsets><italic><offsets xml_i="38043" xml_f="38044" txt_i="23812" txt_f="23813">p</offsets></italic><offsets xml_i="38053" xml_f="38063" txt_i="23813" txt_f="23820">&lt;0.05, </offsets><italic><offsets xml_i="38071" xml_f="38072" txt_i="23820" txt_f="23821">p</offsets></italic><offsets xml_i="38081" xml_f="38091" txt_i="23821" txt_f="23828">&lt;0.01; </offsets><xref ref-type="fig" rid="pone-0077823-g007"><offsets xml_i="38136" xml_f="38137" txt_i="23828" txt_f="23829">
</offsets><bold><offsets xml_i="38143" xml_f="38152" txt_i="23829" txt_f="23838">Figure 7C</offsets></bold><offsets xml_i="38159" xml_f="38160" txt_i="23838" txt_f="23839">
</offsets></xref><offsets xml_i="38167" xml_f="38341" txt_i="23839" txt_f="24013">). After EN treatment, S6K1 phosphorylation increased in both groups, but only with statistical significance observed in the T-HS/EAA group compared with the T-HS/Ctr group (</offsets><italic><offsets xml_i="38349" xml_f="38350" txt_i="24013" txt_f="24014">p</offsets></italic><offsets xml_i="38359" xml_f="38466" txt_i="24014" txt_f="24118">&lt;0.01). Furthermore, phospho-S6K1 levels in the T-HS/EAA group were also higher than the T-HS/SE group (</offsets><italic><offsets xml_i="38474" xml_f="38475" txt_i="24118" txt_f="24119">p</offsets></italic><offsets xml_i="38484" xml_f="38494" txt_i="24119" txt_f="24126">&lt;0.05).</offsets></p><fig id="pone-0077823-g007" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="38595" xml_f="38628" txt_i="24127" txt_f="24160">10.1371/journal.pone.0077823.g007</offsets></object-id><label><offsets xml_i="38647" xml_f="38655" txt_i="24160" txt_f="24168">Figure 7</offsets></label><caption><title><offsets xml_i="38679" xml_f="38758" txt_i="24168" txt_f="24247">Phosphorylations of mTOR related signaling effectors in gastrocnemius at day 6.</offsets></title><p><offsets xml_i="38769" xml_f="39163" txt_i="24248" txt_f="24642">(A) Akt phosphorylation at Ser473 and total Akt. (B) mTOR phosphorylation at Ser2448 and total mTOR. (C) p70S6K1 phosphorylation at Thr389 and total p70S6K1. The density of each western blot is quantified by Quantity One software and the data are presented as mean ± SE in arbitrary unit (AU) from three independent experiments. Groups with different letters indicate a significant difference (</offsets><italic><offsets xml_i="39171" xml_f="39172" txt_i="24642" txt_f="24643">p</offsets></italic><offsets xml_i="39181" xml_f="39191" txt_i="24643" txt_f="24650">&lt;0.05).</offsets></p></caption><graphic xlink:href="pone.0077823.g007"></graphic></fig></sec><sec id="s3e"><title><offsets xml_i="39288" xml_f="39315" txt_i="24652" txt_f="24679">5. Blood EAA Concentrations</offsets></title><p><offsets xml_i="39326" xml_f="39513" txt_i="24680" txt_f="24867">There was no significant decrease in branched chain amino acid (BCAA) concentrations in the T-HS/Ctr group compared with the NC or PF group at day 6, with the exception of valine (vs NC, </offsets><italic><offsets xml_i="39521" xml_f="39522" txt_i="24867" txt_f="24868">p</offsets></italic><offsets xml_i="39531" xml_f="39541" txt_i="24868" txt_f="24875">&lt;0.05; </offsets><xref ref-type="fig" rid="pone-0077823-g008"><offsets xml_i="39586" xml_f="39587" txt_i="24875" txt_f="24876">
</offsets><bold><offsets xml_i="39593" xml_f="39601" txt_i="24876" txt_f="24884">Figure 8</offsets></bold><offsets xml_i="39608" xml_f="39609" txt_i="24884" txt_f="24885">
</offsets></xref><offsets xml_i="39616" xml_f="39828" txt_i="24885" txt_f="25097">). Treatment with standard EN slightly, without significance, increased the blood leucine and isoleucine levels. In contrast, a pronounced increase in BCAA levels was detected in the T-HS/EAA group (vs T-HS/Ctr, </offsets><italic><offsets xml_i="39836" xml_f="39837" txt_i="25097" txt_f="25098">p</offsets></italic><offsets xml_i="39846" xml_f="39957" txt_i="25098" txt_f="25206">&lt;0.01), and the leucine and valine concentrations were even higher than that observed in the T-HS/SE group (</offsets><italic><offsets xml_i="39965" xml_f="39966" txt_i="25206" txt_f="25207">p</offsets></italic><offsets xml_i="39975" xml_f="40110" txt_i="25207" txt_f="25339">&lt;0.01). Similarly, blood levels of other EAA were increased after EN treatment, but with greater in the T-HS/EAA group (vs T-HS/SE, </offsets><italic><offsets xml_i="40118" xml_f="40119" txt_i="25339" txt_f="25340">p</offsets></italic><offsets xml_i="40128" xml_f="40138" txt_i="25340" txt_f="25347">&lt;0.05).</offsets></p><fig id="pone-0077823-g008" orientation="portrait" position="float"><object-id pub-id-type="doi"><offsets xml_i="40239" xml_f="40272" txt_i="25348" txt_f="25381">10.1371/journal.pone.0077823.g008</offsets></object-id><label><offsets xml_i="40291" xml_f="40299" txt_i="25381" txt_f="25389">Figure 8</offsets></label><caption><title><offsets xml_i="40323" xml_f="40374" txt_i="25389" txt_f="25440">Blood essential amino acid concentrations at day 6.</offsets></title><p><offsets xml_i="40385" xml_f="40504" txt_i="25441" txt_f="25560">Values are presented as mean ± SE. Groups with different letters at each time point indicate a significant difference (</offsets><italic><offsets xml_i="40512" xml_f="40513" txt_i="25560" txt_f="25561">p</offsets></italic><offsets xml_i="40522" xml_f="40532" txt_i="25561" txt_f="25568">&lt;0.05).</offsets></p></caption><graphic xlink:href="pone.0077823.g008"></graphic></fig></sec></sec><sec id="s4"><title><offsets xml_i="40634" xml_f="40644" txt_i="25571" txt_f="25581">Discussion</offsets></title><p><offsets xml_i="40655" xml_f="41302" txt_i="25582" txt_f="26229">Sustained suppression of circulating IGF-1 levels is one important metabolic derangement during critical illness, which is implicated in the pathogenesis of impaired muscle protein anabolism. Our study illustrates that EAA enriched high-protein EN favors early recovery of the IGF-1 system in T-HS injured rats, accompanying with the obvious muscle mass maintenance and downstream mTOR pathway activation, which indicates effective stimulation of muscle protein translation initiation. These results provide valuable insight into the metabolic regulation stimulated by high-protein nutrition support during the stress response to critical illness.</offsets></p><p><offsets xml_i="41309" xml_f="41482" txt_i="26230" txt_f="26403">The composition of EAA supplementation used in this study contained a large proportion of leucine. Recently, leucine is shown to be capable of stimulating insulin secretion </offsets><xref rid="pone.0077823-Yang1" ref-type="bibr"><offsets xml_i="41529" xml_f="41533" txt_i="26403" txt_f="26407">[23]</offsets></xref><offsets xml_i="41540" xml_f="41541" txt_i="26407" txt_f="26408">–</offsets><xref rid="pone.0077823-Amaral1" ref-type="bibr"><offsets xml_i="41590" xml_f="41594" txt_i="26408" txt_f="26412">[25]</offsets></xref><offsets xml_i="41601" xml_f="41833" txt_i="26412" txt_f="26644">. This is consistent with our data, which the insulin levels were highest in the T-HS/EAA group by day 4 compared with the T-HS/SE and T-HS/Ctr groups. As reported, insulin is a known regulator to inhibit hepatic IGFBP-1 production </offsets><xref rid="pone.0077823-Frost1" ref-type="bibr"><offsets xml_i="41881" xml_f="41885" txt_i="26644" txt_f="26648">[26]</offsets></xref><offsets xml_i="41892" xml_f="41993" txt_i="26648" txt_f="26749">, and elevated IGFBP-1 levels under catabolic stress can act to inhibit the anabolic effect of IGF-1 </offsets><xref rid="pone.0077823-Lang1" ref-type="bibr"><offsets xml_i="42040" xml_f="42044" txt_i="26749" txt_f="26753">[27]</offsets></xref><offsets xml_i="42051" xml_f="42554" txt_i="26753" txt_f="27256">. In the present study, serum IGFBP-1 concentrations appeared to correlate well with these data, displaying dramatically decreasing levels that were consistent with the increase in circulating insulin levels observed in enterally fed rats at the time point coinciding with the emergence of elevation in serum free IGF-1 levels. And this response appeared more pronounced in the T-HS/EAA group than T-HS/SE group. Regression analysis of insulin and IGF-1 further indicated a strong positive correlation (</offsets><italic><offsets xml_i="42562" xml_f="42563" txt_i="27256" txt_f="27257">y</offsets></italic><offsets xml_i="42572" xml_f="42580" txt_i="27257" txt_f="27265"> = 0.038</offsets><italic><offsets xml_i="42588" xml_f="42589" txt_i="27265" txt_f="27266">x</offsets></italic><offsets xml_i="42598" xml_f="42605" txt_i="27266" txt_f="27273">−1.08; </offsets><italic><offsets xml_i="42613" xml_f="42614" txt_i="27273" txt_f="27274">R</offsets><sup><offsets xml_i="42619" xml_f="42620" txt_i="27274" txt_f="27275">2</offsets></sup></italic><offsets xml_i="42635" xml_f="42645" txt_i="27275" txt_f="27285"> = 0.483; </offsets><italic><offsets xml_i="42653" xml_f="42654" txt_i="27285" txt_f="27286">p</offsets></italic><offsets xml_i="42663" xml_f="42715" txt_i="27286" txt_f="27335">&lt;0.01), which was in line with the previous work </offsets><xref rid="pone.0077823-Wojnar1" ref-type="bibr"><offsets xml_i="42764" xml_f="42768" txt_i="27335" txt_f="27339">[18]</offsets></xref><offsets xml_i="42775" xml_f="42776" txt_i="27339" txt_f="27340">.</offsets></p><p><offsets xml_i="42783" xml_f="42795" txt_i="27341" txt_f="27353">However, Ma </offsets><italic><offsets xml_i="42803" xml_f="42809" txt_i="27353" txt_f="27359">et al.</offsets></italic><offsets xml_i="42818" xml_f="42819" txt_i="27359" txt_f="27360">
</offsets><xref rid="pone.0077823-Ma2" ref-type="bibr"><offsets xml_i="42864" xml_f="42868" txt_i="27360" txt_f="27364">[28]</offsets></xref><offsets xml_i="42875" xml_f="43226" txt_i="27364" txt_f="27715"> found that hepatic IGFBP-1 gene expression was dramatically increased immediately following T-HS along with hyperinsulinemia at 90 and 210 minutes. This does not entirely fit with our results, which appears to depend upon the different time points selected. During the “ebb” phase of injury, insulin levels are commonly decreased or remain unchanged </offsets><xref rid="pone.0077823-Wilmore1" ref-type="bibr"><offsets xml_i="43276" xml_f="43280" txt_i="27715" txt_f="27719">[29]</offsets></xref><offsets xml_i="43287" xml_f="43289" txt_i="27719" txt_f="27721">, </offsets><xref rid="pone.0077823-Carey1" ref-type="bibr"><offsets xml_i="43337" xml_f="43341" txt_i="27721" txt_f="27725">[30]</offsets></xref><offsets xml_i="43348" xml_f="43429" txt_i="27725" txt_f="27806">. Insulin requires the PI3K pathway for inhibition of hepatic IGFBP-1 production </offsets><xref rid="pone.0077823-Guo1" ref-type="bibr"><offsets xml_i="43475" xml_f="43479" txt_i="27806" txt_f="27810">[31]</offsets></xref><offsets xml_i="43486" xml_f="43641" txt_i="27810" txt_f="27965">. Hepatic insulin resistance, characterized by a defect in insulin-induced PI3K-Akt signal transduction, rapidly develops within 90 minutes following T-HS </offsets><xref rid="pone.0077823-Ma2" ref-type="bibr"><offsets xml_i="43686" xml_f="43690" txt_i="27965" txt_f="27969">[28]</offsets></xref><offsets xml_i="43697" xml_f="43775" txt_i="27969" txt_f="28047">, but may have been alleviated within 48 hours post-T-HS in the present study.</offsets></p><p><offsets xml_i="43782" xml_f="44056" txt_i="28048" txt_f="28322">Endogenous glucocorticoids also mediate IGFBP-1 production. Previous work demonstrated that pretreating animals with glucocorticoid receptor antagonist RU486 partially prevented burn-induced increase in IGFBP-1 and further contributed to the increase in plasma IGF-1 levels </offsets><xref rid="pone.0077823-Lang2" ref-type="bibr"><offsets xml_i="44103" xml_f="44107" txt_i="28322" txt_f="28326">[32]</offsets></xref><offsets xml_i="44114" xml_f="44324" txt_i="28326" txt_f="28536">. The enterally fed rats in the present study appeared to have an early reduction in serum corticosterone levels following T-HS, which is possibly related to the modulation of host defense by enteral nutrients </offsets><xref rid="pone.0077823-Minard1" ref-type="bibr"><offsets xml_i="44373" xml_f="44377" txt_i="28536" txt_f="28540">[33]</offsets></xref><offsets xml_i="44384" xml_f="44508" txt_i="28540" txt_f="28664">. This change was correlated with decreased IGFBP-1 as well as increased IGF-1 levels following 3 days of nutrition support.</offsets></p><p><offsets xml_i="44515" xml_f="44697" txt_i="28665" txt_f="28847">Previous studies using a similar EAA formula or leucine alone to investigate the stimulatory effect upon skeletal muscle protein synthesis did not demonstrate changes in serum IGF-1 </offsets><xref rid="pone.0077823-Fujita1" ref-type="bibr"><offsets xml_i="44746" xml_f="44750" txt_i="28847" txt_f="28851">[20]</offsets></xref><offsets xml_i="44757" xml_f="44759" txt_i="28851" txt_f="28853">, </offsets><xref rid="pone.0077823-Pedrosa1" ref-type="bibr"><offsets xml_i="44809" xml_f="44813" txt_i="28853" txt_f="28857">[34]</offsets></xref><offsets xml_i="44820" xml_f="44822" txt_i="28857" txt_f="28859">, </offsets><xref rid="pone.0077823-Lang3" ref-type="bibr"><offsets xml_i="44869" xml_f="44873" txt_i="28859" txt_f="28863">[35]</offsets></xref><offsets xml_i="44880" xml_f="45413" txt_i="28863" txt_f="29396">. Despite various experimental conditions, those studies measured total IGF-1, instead of free levels. Meanwhile, acute dosing of EAA or leucine solution on the background of inadequate nutrient availability is not sufficient for stimulation of IGF-1 production. In our study, we provided a high-protein diet to the T-HS/EAA animals, with additional EAA supplementation based on the standard EN formula, to investigate the changes in free IGF-1 levels, which represent the “bioavailable” portion of the IGF-1 pool in the circulation </offsets><xref rid="pone.0077823-Foster1" ref-type="bibr"><offsets xml_i="45462" xml_f="45466" txt_i="29396" txt_f="29400">[16]</offsets></xref><offsets xml_i="45473" xml_f="45773" txt_i="29400" txt_f="29700">. Our study indicated that feeding with EAA enriched high-protein EN greatly increased serum free IGF-1 levels compared with the standard EN-fed rats as early as at day 4. This is a desirable outcome, since it has been concluded that IGF-1 plays an important role in skeletal muscle mass maintenance </offsets><xref rid="pone.0077823-Yang2" ref-type="bibr"><offsets xml_i="45820" xml_f="45824" txt_i="29700" txt_f="29704">[36]</offsets></xref><offsets xml_i="45831" xml_f="45995" txt_i="29704" txt_f="29868">. In our study, significantly increased muscle mass, especially in the fast-twitch gastrocnemius muscle, was identified 2 days following T-HS in the T-HS/EAA group.</offsets></p><p><offsets xml_i="46002" xml_f="46663" txt_i="29869" txt_f="30530">We also detected that EAA enriched high-protein EN significantly enhanced the activation of mTOR signaling pathway; phosphorylations of mTOR and its downstream effector S6K1 in rats receiving EAA enriched high-protein formula increased nearly two-fold compared with those receiving standard EN. Recently, a large body of evidence has established that amino acid, especially leucine, can be considered as a signaling molecule to stimulate protein translation initiation through an Akt-independent pathway. Acute leucine ingestion can effectively increase protein synthesis and promote the mTOR-related signaling transduction in both normal and stress conditions </offsets><xref rid="pone.0077823-Dickinson1" ref-type="bibr"><offsets xml_i="46715" xml_f="46719" txt_i="30530" txt_f="30534">[37]</offsets></xref><offsets xml_i="46726" xml_f="46727" txt_i="30534" txt_f="30535">–</offsets><xref rid="pone.0077823-Chen1" ref-type="bibr"><offsets xml_i="46774" xml_f="46778" txt_i="30535" txt_f="30539">[39]</offsets></xref><offsets xml_i="46785" xml_f="46863" txt_i="30539" txt_f="30617">. The stimulation of muscle protein synthesis, as previously reported by Bohé </offsets><italic><offsets xml_i="46871" xml_f="46877" txt_i="30617" txt_f="30623">et al.</offsets></italic><offsets xml_i="46886" xml_f="46887" txt_i="30623" txt_f="30624">
</offsets><xref rid="pone.0077823-Boh1" ref-type="bibr"><offsets xml_i="46933" xml_f="46937" txt_i="30624" txt_f="30628">[40]</offsets></xref><offsets xml_i="46944" xml_f="47374" txt_i="30628" txt_f="31058">, was positively associated with blood EAA concentrations in a dose-response manner. In our study, blood amino acid analysis revealed that leucine and other EAA were significantly increased after EAA enriched high-protein EN treatment. Thus, we speculate that the response to muscle protein translation initiation induced by EAA enriched high-protein EN may be partly attributed to the nutrient-mediated mTOR signaling regulation.</offsets></p><p><offsets xml_i="47381" xml_f="47764" txt_i="31059" txt_f="31442">The PI3K-Akt pathway, upstream of mTOR, can be phosphorylated by ligands including IGF-1 and insulin and that in turn stimulates the mTOR phosphorylation to induce the muscle protein translation initiation. Previous studies demonstrated the rapid development of insulin resistance in skeletal muscle following T-HS, with the earliest insulin signaling defect occurring at 60 minutes </offsets><xref rid="pone.0077823-Chaudry1" ref-type="bibr"><offsets xml_i="47814" xml_f="47818" txt_i="31442" txt_f="31446">[41]</offsets></xref><offsets xml_i="47825" xml_f="47827" txt_i="31446" txt_f="31448">, </offsets><xref rid="pone.0077823-Li1" ref-type="bibr"><offsets xml_i="47872" xml_f="47876" txt_i="31448" txt_f="31452">[42]</offsets></xref><offsets xml_i="47883" xml_f="47890" txt_i="31452" txt_f="31459">. Zhai </offsets><italic><offsets xml_i="47898" xml_f="47904" txt_i="31459" txt_f="31465">et al.</offsets></italic><offsets xml_i="47913" xml_f="47914" txt_i="31465" txt_f="31466">
</offsets><xref rid="pone.0077823-Zhai1" ref-type="bibr"><offsets xml_i="47961" xml_f="47965" txt_i="31466" txt_f="31470">[43]</offsets></xref><offsets xml_i="47972" xml_f="48178" txt_i="31470" txt_f="31676"> further indicated that the T-HS-induced acute muscle insulin resistance was specific to 6- and 10- week old rats, but not the post-weaning. However, the insulin signaling defect is not permanent. Thompson </offsets><italic><offsets xml_i="48186" xml_f="48192" txt_i="31676" txt_f="31682">et al.</offsets></italic><offsets xml_i="48201" xml_f="48202" txt_i="31682" txt_f="31683">
</offsets><xref rid="pone.0077823-Thompson1" ref-type="bibr"><offsets xml_i="48253" xml_f="48257" txt_i="31683" txt_f="31687">[44]</offsets></xref><offsets xml_i="48264" xml_f="48700" txt_i="31687" txt_f="32123"> reported that insulin-induced phospho-Akt signaling in skeletal muscle would be gradually restored by 5 and 24 hours following fluid resuscitation. Therefore, it can reasonably be inferred that muscle insulin resistance is a metabolic feature in the acute phase of T-HS, and the diminished signaling transduction associated with the PI3K-Akt pathway may be partially responsible for the increased muscle protein wasting following T-HS.</offsets></p><p><offsets xml_i="48707" xml_f="49251" txt_i="32124" txt_f="32668">In our study, three later time points following T-HS were selected. Activated Akt was observed at day 6 in both enterally fed groups, but with greater in rats receiving EAA enriched high-protein EN, coinciding with the emergence of significant elevation in both insulin and IGF-1 levels. Previous studies demonstrated the protein retention effect of insulin was likely to be exerted by reducing the protein catabolism after trauma or surgery, because no correlation between changes in muscle protein synthesis and insulin sensitivity was found </offsets><xref rid="pone.0077823-Thorell1" ref-type="bibr"><offsets xml_i="49301" xml_f="49305" txt_i="32668" txt_f="32672">[45]</offsets></xref><offsets xml_i="49312" xml_f="49314" txt_i="32672" txt_f="32674">, </offsets><xref rid="pone.0077823-Thorell2" ref-type="bibr"><offsets xml_i="49364" xml_f="49368" txt_i="32674" txt_f="32678">[46]</offsets></xref><offsets xml_i="49375" xml_f="49537" txt_i="32678" txt_f="32840">. However, administration of IGF-1 effectively attenuates the inhibition of protein synthesis in sepsis or trauma and further ameliorates the loss of muscle mass </offsets><xref rid="pone.0077823-Nystrom1" ref-type="bibr"><offsets xml_i="49587" xml_f="49591" txt_i="32840" txt_f="32844">[47]</offsets></xref><offsets xml_i="49598" xml_f="49600" txt_i="32844" txt_f="32846">, </offsets><xref rid="pone.0077823-Svanberg1" ref-type="bibr"><offsets xml_i="49651" xml_f="49655" txt_i="32846" txt_f="32850">[48]</offsets></xref><offsets xml_i="49662" xml_f="49859" txt_i="32850" txt_f="33047">. Therefore, in addition to the nutrient-dependent mechanism described above, the increased mTOR anabolic signaling in the T-HS/EAA group may be partially due to IGF-1 signaling pathway activation.</offsets></p><p><offsets xml_i="49866" xml_f="50337" txt_i="33048" txt_f="33519">A limitation to the current study is that it is not yet clear whether the increased serum free IGF-1 levels following EAA-enriched high-protein EN are due to the overall increase in IGF-1 production or reduced IGF-1 degradation. As mentioned previously, IGFBP-3 has been shown to be regulated by proteolysis. Increasing proteolytic cleavage of IGFBP-3 causes a decreased affinity for IGF-1, which is responsible for the decrease in circulating IGF-1 levels during stress </offsets><xref rid="pone.0077823-Belizon1" ref-type="bibr"><offsets xml_i="50387" xml_f="50391" txt_i="33519" txt_f="33523">[49]</offsets></xref><offsets xml_i="50398" xml_f="50768" txt_i="33523" txt_f="33893">. In the present study, high serum free IGF-1 levels were observed in the T-HS/EAA group, which were quite consistent with increased IGFBP-3 concentrations. Therefore, further study is required to investigate the IGFBP-3 proteolysis activity and total IGF-1 levels following nutrition support, using a T-HS injured rat model, to make a better interpretation of our data </offsets><xref rid="pone.0077823-Foster1" ref-type="bibr"><offsets xml_i="50817" xml_f="50821" txt_i="33893" txt_f="33897">[16]</offsets></xref><offsets xml_i="50828" xml_f="50829" txt_i="33897" txt_f="33898">.</offsets></p><p><offsets xml_i="50836" xml_f="51629" txt_i="33899" txt_f="34692">In summary, our findings firstly demonstrate the effect of EAA enriched high-protein EN upon the metabolic regulation of skeletal muscle protein anabolism by regulating the IGF-1 system and downstream anabolic signaling transduction. We demonstrated that early nutrition support favored the recovery of serum free IGF-1 levels following T-HS, and the EAA enriched high-protein EN treatment appeared more effective. It was beneficial for the muscle mass maintenance in T-HS injured rats. Moreover, long-term treatment with EAA enriched high-protein EN effectively activated the mTOR related translation initiation factors, indicating the stimulation of muscle protein synthesis. And this response might be based on cooperation between IGF-1- and nutrient- mediated signal transduction pathways.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="pone.0077823-Biolo1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Biolo</surname><given-names>G</given-names></name>, <name><surname>Toigo</surname><given-names>G</given-names></name>, <name><surname>Ciocchi</surname><given-names>B</given-names></name>, <name><surname>Situlin</surname><given-names>R</given-names></name>, <name><surname>Iscra</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>1997</year>) <article-title>Metabolic response to injury and sepsis: Changes in protein metabolism</article-title>. <source>Nutrition</source>
<volume>13</volume>: <fpage>S52</fpage>–<lpage>S57</lpage>.</mixed-citation></ref><ref id="pone.0077823-Skipworth1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Skipworth</surname><given-names>RJE</given-names></name>, <name><surname>Stewart</surname><given-names>GD</given-names></name>, <name><surname>Ross</surname><given-names>JA</given-names></name>, <name><surname>Guttridge</surname><given-names>DC</given-names></name>, <name><surname>Fearon</surname><given-names>KCH</given-names></name> (<year>2006</year>) <article-title>The molecular mechanisms of skeletal muscle wasting: Implications for therapy</article-title>. <source>Surgeon</source>
<volume>4</volume>: <fpage>273</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">17009546</pub-id></mixed-citation></ref><ref id="pone.0077823-Klaude1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Klaude</surname><given-names>M</given-names></name>, <name><surname>Mori</surname><given-names>M</given-names></name>, <name><surname>Tjader</surname><given-names>I</given-names></name>, <name><surname>Gustafsson</surname><given-names>T</given-names></name>, <name><surname>Wernerman</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis</article-title>. <source>Clin Sci (Lond)</source>
<volume>122</volume>: <fpage>133</fpage>–<lpage>142</lpage>.</mixed-citation></ref><ref id="pone.0077823-Okamoto1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Okamoto</surname><given-names>I</given-names></name>, <name><surname>Munakata</surname><given-names>M</given-names></name>, <name><surname>Miyazaki</surname><given-names>M</given-names></name>, <name><surname>Satoh</surname><given-names>T</given-names></name>, <name><surname>Takahata</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors</article-title>. <source>Jpn J Clin Oncol</source>
<volume>40</volume>: <fpage>222</fpage>–<lpage>226</lpage>.<pub-id pub-id-type="pmid">19942582</pub-id></mixed-citation></ref><ref id="pone.0077823-Elijah1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Elijah</surname><given-names>IE</given-names></name>, <name><surname>Branski</surname><given-names>LK</given-names></name>, <name><surname>Finnerty</surname><given-names>CC</given-names></name>, <name><surname>Herndon</surname><given-names>DN</given-names></name> (<year>2011</year>) <article-title>The GH/IGF-1 system in critical illness</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source>
<volume>25</volume>: <fpage>759</fpage>–<lpage>767</lpage>.<pub-id pub-id-type="pmid">21925076</pub-id></mixed-citation></ref><ref id="pone.0077823-Janssen1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Janssen</surname><given-names>J</given-names></name>, <name><surname>Van der Lely</surname><given-names>A</given-names></name>, <name><surname>Lamberts</surname><given-names>S</given-names></name> (<year>2003</year>) <article-title>Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity</article-title>. <source>J Endocrinol Invest</source>
<volume>26</volume>: <fpage>588</fpage>–<lpage>594</lpage>.<pub-id pub-id-type="pmid">12952376</pub-id></mixed-citation></ref><ref id="pone.0077823-Clemmons1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Clemmons</surname><given-names>DR</given-names></name> (<year>2009</year>) <article-title>Role of IGF-I in skeletal muscle mass maintenance</article-title>. <source>Trends Endocrinol Metab</source>
<volume>20</volume>: <fpage>349</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">19729319</pub-id></mixed-citation></ref><ref id="pone.0077823-Howell1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Howell</surname><given-names>JJ</given-names></name>, <name><surname>Manning</surname><given-names>BD</given-names></name> (<year>2011</year>) <article-title>mTOR couples cellular nutrient sensing to organismal metabolic homeostasis</article-title>. <source>Trends Endocrinol Metab</source>
<volume>22</volume>: <fpage>94</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">21269838</pub-id></mixed-citation></ref><ref id="pone.0077823-Ma1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>XM</given-names></name>, <name><surname>Blenis</surname><given-names>J</given-names></name> (<year>2009</year>) <article-title>Molecular mechanisms of mTOR-mediated translational control</article-title>. <source>Nat Rev Mol Cell Biol</source>
<volume>10</volume>: <fpage>307</fpage>–<lpage>318</lpage>.<pub-id pub-id-type="pmid">19339977</pub-id></mixed-citation></ref><ref id="pone.0077823-Kelley1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Kelley</surname><given-names>KM</given-names></name>, <name><surname>Oh</surname><given-names>Y</given-names></name>, <name><surname>Gargosky</surname><given-names>SE</given-names></name>, <name><surname>Gucev</surname><given-names>Z</given-names></name>, <name><surname>Matsumoto</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics</article-title>. <source>Int J Biochem Cell Biol</source>
<volume>28</volume>: <fpage>619</fpage>–<lpage>637</lpage>.<pub-id pub-id-type="pmid">8673727</pub-id></mixed-citation></ref><ref id="pone.0077823-Gomes1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Gomes</surname><given-names>M</given-names></name>, <name><surname>Oliveira Pires</surname><given-names>I</given-names></name>, <name><surname>Castro</surname><given-names>I</given-names></name>, <name><surname>Tirapegui</surname><given-names>J</given-names></name> (<year>2003</year>) <article-title>Effect of protein restriction on plasma and tissue levels of insulin-like growth factor-1 (IGF-1) in adult rats</article-title>. <source>Nutr Res</source>
<volume>23</volume>: <fpage>1239</fpage>–<lpage>1250</lpage>.</mixed-citation></ref><ref id="pone.0077823-SanchezGomez1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Sanchez-Gomez</surname><given-names>M</given-names></name>, <name><surname>Malmlöf</surname><given-names>K</given-names></name>, <name><surname>Mejia</surname><given-names>W</given-names></name>, <name><surname>Bermudez</surname><given-names>A</given-names></name>, <name><surname>Ochoa</surname><given-names>MT</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Insulin-like growth factor-I, but not growth hormone, is dependent on a high protein intake to increase nitrogen balance in the rat</article-title>. <source>Br J Nutr</source>
<volume>81</volume>: <fpage>145</fpage>–<lpage>152</lpage>.<pub-id pub-id-type="pmid">10450333</pub-id></mixed-citation></ref><ref id="pone.0077823-Chevalley1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Chevalley</surname><given-names>T</given-names></name>, <name><surname>Hoffmeyer</surname><given-names>P</given-names></name>, <name><surname>Bonjour</surname><given-names>JP</given-names></name>, <name><surname>Rizzoli</surname><given-names>R</given-names></name> (<year>2010</year>) <article-title>Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture</article-title>. <source>Clin Nutr</source>
<volume>29</volume>: <fpage>78</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">19660844</pub-id></mixed-citation></ref><ref id="pone.0077823-Wallin1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Wallin</surname><given-names>M</given-names></name>, <name><surname>Selldén</surname><given-names>E</given-names></name>, <name><surname>Eksborg</surname><given-names>S</given-names></name>, <name><surname>Brismar</surname><given-names>K</given-names></name> (<year>2007</year>) <article-title>Amino acid infusion during anesthesia attenuates the surgery induced decline in IGF-1 and diminishes the “diabetes of injury”</article-title>. Nutr Metab (Lond). <volume>4</volume>: <fpage>2</fpage>.</mixed-citation></ref><ref id="pone.0077823-Takenaka1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Takenaka</surname><given-names>A</given-names></name>, <name><surname>Oki</surname><given-names>N</given-names></name>, <name><surname>Takahashi</surname><given-names>S-I</given-names></name>, <name><surname>Noguchi</surname><given-names>T</given-names></name> (<year>2000</year>) <article-title>Dietary restriction of single essential amino acids reduces plasma insulin-like growth factor-I (IGF-I) but does not affect plasma IGF-binding protein-1 in rats</article-title>. <source>J Nutr</source>
<volume>130</volume>: <fpage>2910</fpage>–<lpage>2914</lpage>.<pub-id pub-id-type="pmid">11110845</pub-id></mixed-citation></ref><ref id="pone.0077823-Foster1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Foster</surname><given-names>EB</given-names></name>, <name><surname>Fisher</surname><given-names>G</given-names></name>, <name><surname>Sartin</surname><given-names>JL</given-names></name>, <name><surname>Elsasser</surname><given-names>TH</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Acute regulation of IGF-I by alterations in post-exercise macronutrients</article-title>. <source>Amino Acids</source>
<volume>42</volume>: <fpage>1405</fpage>–<lpage>1416</lpage>.<pub-id pub-id-type="pmid">21293890</pub-id></mixed-citation></ref><ref id="pone.0077823-McClave1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>McClave</surname><given-names>SA</given-names></name>, <name><surname>Martindale</surname><given-names>RG</given-names></name>, <name><surname>Vanek</surname><given-names>VW</given-names></name>, <name><surname>McGarthy</surname><given-names>M</given-names></name>, <name><surname>Roberts</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)</article-title>. <source>JPEN J Parenter Enteral Nutr</source>
<volume>33</volume>: <fpage>277</fpage>–<lpage>316</lpage>.<pub-id pub-id-type="pmid">19398613</pub-id></mixed-citation></ref><ref id="pone.0077823-Wojnar1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Wojnar</surname><given-names>MM</given-names></name>, <name><surname>Fan</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>YH</given-names></name>, <name><surname>Lang</surname><given-names>CH</given-names></name> (<year>1999</year>) <article-title>Endotoxin-induced changes in IGF-I differ in rats provided enteral vs. parenteral nutrition</article-title>. <source>Am J Physiol</source>
<volume>276</volume>: <fpage>E455</fpage>–<lpage>E464</lpage>.<pub-id pub-id-type="pmid">10070010</pub-id></mixed-citation></ref><ref id="pone.0077823-Katsanos1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Katsanos</surname><given-names>CS</given-names></name>, <name><surname>Kobayashi</surname><given-names>H</given-names></name>, <name><surname>Sheffield-Moore</surname><given-names>M</given-names></name>, <name><surname>Aarsland</surname><given-names>A</given-names></name>, <name><surname>Wolfe</surname><given-names>RR</given-names></name> (<year>2006</year>) <article-title>A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<volume>291</volume>: <fpage>E381</fpage>–<lpage>E387</lpage>.<pub-id pub-id-type="pmid">16507602</pub-id></mixed-citation></ref><ref id="pone.0077823-Fujita1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Fujita</surname><given-names>S</given-names></name>, <name><surname>Dreyer</surname><given-names>HC</given-names></name>, <name><surname>Drummond</surname><given-names>MJ</given-names></name>, <name><surname>Glynn</surname><given-names>EL</given-names></name>, <name><surname>Cadenas</surname><given-names>JG</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Nutrient signalling in the regulation of human muscle protein synthesis</article-title>. <source>J Physiol</source>
<volume>582</volume>: <fpage>813</fpage>–<lpage>823</lpage>.<pub-id pub-id-type="pmid">17478528</pub-id></mixed-citation></ref><ref id="pone.0077823-Wang1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Proud</surname><given-names>CG</given-names></name> (<year>2007</year>) <article-title>Methods for studying signal-dependent regulation of translation factor activity</article-title>. <source>Methods Enzymol</source>
<volume>431</volume>: <fpage>113</fpage>–<lpage>113</lpage>.<pub-id pub-id-type="pmid">17923233</pub-id></mixed-citation></ref><ref id="pone.0077823-Luo1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Luo</surname><given-names>N</given-names></name>, <name><surname>Liu</surname><given-names>FN</given-names></name>, <name><surname>Tan</surname><given-names>L</given-names></name>, <name><surname>Jiang</surname><given-names>XH</given-names></name>, <name><surname>Zhu</surname><given-names>WM</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>The measurement of serum amino acids in short bowel syndrome patients</article-title>. <source>Parenteral &amp; Enteral Nutrition</source>
<volume>6</volume>: <fpage>367</fpage>–<lpage>368</lpage>.</mixed-citation></ref><ref id="pone.0077823-Yang1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Dolinger</surname><given-names>M</given-names></name>, <name><surname>Ritaccio</surname><given-names>G</given-names></name>, <name><surname>Mazurkiewicz</surname><given-names>J</given-names></name>, <name><surname>Conti</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Leucine stimulates insulin secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of rapamycin) pathway: implication in new-onset diabetes in renal transplantation</article-title>. <source>J Biol Chem</source>
<volume>287</volume>: <fpage>24795</fpage>–<lpage>24806</lpage>.<pub-id pub-id-type="pmid">22645144</pub-id></mixed-citation></ref><ref id="pone.0077823-Macotela1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Macotela</surname><given-names>Y</given-names></name>, <name><surname>Emanuelli</surname><given-names>B</given-names></name>, <name><surname>Bang</surname><given-names>AM</given-names></name>, <name><surname>Espinoza</surname><given-names>DO</given-names></name>, <name><surname>Boucher</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Dietary Leucine - An Environmental Modifier of Insulin Resistance Acting on Multiple Levels of Metabolism</article-title>. <source>PLoS ONE</source>
<volume>6</volume>: <fpage>e21187</fpage>
<comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0021187">10.1371/journal.pone.0021187</ext-link></comment>
<pub-id pub-id-type="pmid">21731668</pub-id></mixed-citation></ref><ref id="pone.0077823-Amaral1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Amaral</surname><given-names>AG</given-names></name>, <name><surname>Rafacho</surname><given-names>A</given-names></name>, <name><surname>de Oliveira</surname><given-names>CAM</given-names></name>, <name><surname>Batista</surname><given-names>TM</given-names></name>, <name><surname>Ribeiro</surname><given-names>RA</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Leucine supplementation augments insulin secretion in pancreatic islets of malnourished mice</article-title>. <source>Pancreas</source>
<volume>39</volume>: <fpage>847</fpage>–<lpage>855</lpage>.<pub-id pub-id-type="pmid">20697208</pub-id></mixed-citation></ref><ref id="pone.0077823-Frost1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Frost</surname><given-names>RA</given-names></name>, <name><surname>Lang</surname><given-names>CH</given-names></name> (<year>1999</year>) <article-title>Differential effects of insulin-like growth factor I (IGF-I) and IGF-binding protein-1 on protein metabolism in human skeletal muscle cells</article-title>. <source>Endocrinology</source>
<volume>140</volume>: <fpage>3962</fpage>–<lpage>3970</lpage>.<pub-id pub-id-type="pmid">10465265</pub-id></mixed-citation></ref><ref id="pone.0077823-Lang1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Lang</surname><given-names>CH</given-names></name>, <name><surname>Vary</surname><given-names>TC</given-names></name>, <name><surname>Frost</surname><given-names>RA</given-names></name> (<year>2003</year>) <article-title>Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis</article-title>. <source>Endocrinology</source>
<volume>144</volume>: <fpage>3922</fpage>–<lpage>3933</lpage>.<pub-id pub-id-type="pmid">12933666</pub-id></mixed-citation></ref><ref id="pone.0077823-Ma2"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <name><surname>Kuebler</surname><given-names>JF</given-names></name>, <name><surname>Chaudry</surname><given-names>IH</given-names></name>, <name><surname>Messina</surname><given-names>JL</given-names></name> (<year>2003</year>) <article-title>Hemorrhage induces the rapid development of hepatic insulin resistance</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>
<volume>284</volume>: <fpage>G107</fpage>–<lpage>G115</lpage>.<pub-id pub-id-type="pmid">12388175</pub-id></mixed-citation></ref><ref id="pone.0077823-Wilmore1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Wilmore</surname><given-names>DW</given-names></name>, <name><surname>Mason</surname><given-names>AD</given-names><suffix>Jr</suffix></name>, <name><surname>Pruitt</surname><given-names>BA</given-names><suffix>Jr</suffix></name> (<year>1976</year>) <article-title>Insulin response to glucose in hypermetabolic burn patients</article-title>. <source>Ann Surg</source>
<volume>183</volume>: <fpage>314</fpage>–<lpage>320</lpage>.<pub-id pub-id-type="pmid">1259488</pub-id></mixed-citation></ref><ref id="pone.0077823-Carey1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Carey</surname><given-names>LC</given-names></name>, <name><surname>Lowery</surname><given-names>BD</given-names></name>, <name><surname>Cloutier</surname><given-names>CT</given-names></name> (<year>1970</year>) <article-title>Blood sugar and insulin response of humans in shock</article-title>. <source>Ann Surg</source>
<volume>172</volume>: <fpage>342</fpage>–<lpage>350</lpage>.<pub-id pub-id-type="pmid">5459093</pub-id></mixed-citation></ref><ref id="pone.0077823-Guo1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Guo</surname><given-names>S</given-names></name>, <name><surname>Rena</surname><given-names>G</given-names></name>, <name><surname>Cichy</surname><given-names>S</given-names></name>, <name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Cohen</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence</article-title>. <source>J Biol Chem</source>
<volume>274</volume>: <fpage>17184</fpage>–<lpage>17192</lpage>.<pub-id pub-id-type="pmid">10358076</pub-id></mixed-citation></ref><ref id="pone.0077823-Lang2"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Lang</surname><given-names>CH</given-names></name>, <name><surname>Nystrom</surname><given-names>GJ</given-names></name>, <name><surname>Frost</surname><given-names>RA</given-names></name> (<year>2002</year>) <article-title>Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>
<volume>282</volume>: <fpage>R207</fpage>–<lpage>R215</lpage>.<pub-id pub-id-type="pmid">11742840</pub-id></mixed-citation></ref><ref id="pone.0077823-Minard1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Minard</surname><given-names>G</given-names></name>, <name><surname>Kudsk</surname><given-names>KA</given-names></name> (<year>1998</year>) <article-title>Nutritional support and infection: does the route matter?</article-title>
<source>World J Surg</source>
<volume>22</volume>: <fpage>213</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="pmid">9451939</pub-id></mixed-citation></ref><ref id="pone.0077823-Pedrosa1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Pedrosa</surname><given-names>RG</given-names></name>, <name><surname>Donato</surname><given-names>J</given-names></name>, <name><surname>Pires</surname><given-names>IS</given-names></name>, <name><surname>Tirapegui</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>Leucine supplementation favors liver protein status but does not reduce body fat in rats during 1 week of food restriction</article-title>. <source>Appl Physiol Nutr Metab</source>
<volume>35</volume>: <fpage>180</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">20383228</pub-id></mixed-citation></ref><ref id="pone.0077823-Lang3"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Lang</surname><given-names>CH</given-names></name>, <name><surname>Deshpande</surname><given-names>N</given-names></name>, <name><surname>Frost</surname><given-names>RA</given-names></name> (<year>2004</year>) <article-title>Leucine acutely reverses burn-induced alterations in translation initiation in heart</article-title>. <source>Shock</source>
<volume>22</volume>: <fpage>326</fpage>–<lpage>332</lpage>.<pub-id pub-id-type="pmid">15377887</pub-id></mixed-citation></ref><ref id="pone.0077823-Yang2"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Yang</surname><given-names>SY</given-names></name>, <name><surname>Hoy</surname><given-names>M</given-names></name>, <name><surname>Fuller</surname><given-names>B</given-names></name>, <name><surname>Sales</surname><given-names>KM</given-names></name>, <name><surname>Seifalian</surname><given-names>AM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways</article-title>. <source>Lab Invest</source>
<volume>90</volume>: <fpage>391</fpage>–<lpage>401</lpage>.<pub-id pub-id-type="pmid">20084055</pub-id></mixed-citation></ref><ref id="pone.0077823-Dickinson1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Dickinson</surname><given-names>JM</given-names></name>, <name><surname>Fry</surname><given-names>CS</given-names></name>, <name><surname>Drummond</surname><given-names>MJ</given-names></name>, <name><surname>Gundermann</surname><given-names>DM</given-names></name>, <name><surname>Walker</surname><given-names>DK</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids</article-title>. <source>J Nutr</source>
<volume>141</volume>: <fpage>856</fpage>–<lpage>862</lpage>.<pub-id pub-id-type="pmid">21430254</pub-id></mixed-citation></ref><ref id="pone.0077823-Pasiakos1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Pasiakos</surname><given-names>SM</given-names></name>, <name><surname>McClung</surname><given-names>HL</given-names></name>, <name><surname>McClung</surname><given-names>JP</given-names></name>, <name><surname>Margolis</surname><given-names>LM</given-names></name>, <name><surname>Andersen</surname><given-names>NE</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Leucine-enriched essential amino acid supplementation during moderate steady state exercise enhances postexercise muscle protein synthesis</article-title>. <source>Am J Clin Nutr</source>
<volume>94</volume>: <fpage>809</fpage>–<lpage>818</lpage>.<pub-id pub-id-type="pmid">21775557</pub-id></mixed-citation></ref><ref id="pone.0077823-Chen1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Sood</surname><given-names>S</given-names></name>, <name><surname>McIntire</surname><given-names>K</given-names></name>, <name><surname>Roth</surname><given-names>R</given-names></name>, <name><surname>Rabkin</surname><given-names>R</given-names></name> (<year>2011</year>) <article-title>Leucine-stimulated mTOR signaling is partly attenuated in skeletal muscle of chronically uremic rats</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<volume>301</volume>: <fpage>E873</fpage>–<lpage>E881</lpage>.<pub-id pub-id-type="pmid">21791619</pub-id></mixed-citation></ref><ref id="pone.0077823-Boh1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Bohé</surname><given-names>J</given-names></name>, <name><surname>Low</surname><given-names>A</given-names></name>, <name><surname>Wolfe</surname><given-names>RR</given-names></name>, <name><surname>Rennie</surname><given-names>MJ</given-names></name> (<year>2003</year>) <article-title>Human muscle protein synthesis is modulated by extracellular, not intramuscular amino acid availability: a dose-response study</article-title>. <source>J Physiol</source>
<volume>552</volume>: <fpage>315</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">12909668</pub-id></mixed-citation></ref><ref id="pone.0077823-Chaudry1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Chaudry</surname><given-names>IH</given-names></name>, <name><surname>Sayeed</surname><given-names>MM</given-names></name>, <name><surname>Baue</surname><given-names>AE</given-names></name> (<year>1976</year>) <article-title>Insulin resistance and its reversal by in vivo infusion of ATP in hemorrhagic shock</article-title>. <source>Can J Physiol Pharmacol</source>
<volume>54</volume>: <fpage>736</fpage>–<lpage>741</lpage>.<pub-id pub-id-type="pmid">991003</pub-id></mixed-citation></ref><ref id="pone.0077823-Li1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Thompson</surname><given-names>LH</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Messina</surname><given-names>JL</given-names></name> (<year>2009</year>) <article-title>Tissue-specific difference in the molecular mechanisms for the development of acute insulin resistance after injury</article-title>. <source>Endocrinology</source>
<volume>150</volume>: <fpage>24</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">18801909</pub-id></mixed-citation></ref><ref id="pone.0077823-Zhai1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Zhai</surname><given-names>L</given-names></name>, <name><surname>Messina</surname><given-names>JL</given-names></name> (<year>2009</year>) <article-title>Age and tissue specific differences in the development of acute insulin resistance following injury</article-title>. <source>J Endocrinol</source>
<volume>203</volume>: <fpage>365</fpage>–<lpage>374</lpage>.<pub-id pub-id-type="pmid">19752148</pub-id></mixed-citation></ref><ref id="pone.0077823-Thompson1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Thompson</surname><given-names>LH</given-names></name>, <name><surname>Kim</surname><given-names>HT</given-names></name>, <name><surname>Ma</surname><given-names>Y</given-names></name>, <name><surname>Kokorina</surname><given-names>NA</given-names></name>, <name><surname>Messina</surname><given-names>JL</given-names></name> (<year>2008</year>) <article-title>Acute, muscle-type specific insulin resistance following injury</article-title>. <source>Mol Med</source>
<volume>14</volume>: <fpage>715</fpage>–<lpage>723</lpage>.<pub-id pub-id-type="pmid">19009015</pub-id></mixed-citation></ref><ref id="pone.0077823-Thorell1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Thorell</surname><given-names>A</given-names></name>, <name><surname>Nygren</surname><given-names>J</given-names></name>, <name><surname>Ljungqvist</surname><given-names>O</given-names></name> (<year>1999</year>) <article-title>Insulin resistance: a marker of surgical stress</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>
<volume>2</volume>: <fpage>69</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">10453333</pub-id></mixed-citation></ref><ref id="pone.0077823-Thorell2"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Thorell</surname><given-names>A</given-names></name>, <name><surname>Essen</surname><given-names>P</given-names></name>, <name><surname>Ljungqvist</surname><given-names>O</given-names></name>, <name><surname>McNurlan</surname><given-names>M</given-names></name>, <name><surname>Calder</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>Postoperative insulin resistance and muscle protein synthesis rate</article-title>. <source>Clin Nutr</source>
<volume>11</volume>: <fpage>48</fpage>.<pub-id pub-id-type="pmid">16839970</pub-id></mixed-citation></ref><ref id="pone.0077823-Nystrom1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Nystrom</surname><given-names>G</given-names></name>, <name><surname>Pruznak</surname><given-names>A</given-names></name>, <name><surname>Huber</surname><given-names>D</given-names></name>, <name><surname>Frost</surname><given-names>RA</given-names></name>, <name><surname>Lang</surname><given-names>CH</given-names></name> (<year>2009</year>) <article-title>Local insulin-like growth factor I prevents sepsis-induced muscle atrophy</article-title>. <source>Metabolism</source>
<volume>58</volume>: <fpage>787</fpage>–<lpage>797</lpage>.<pub-id pub-id-type="pmid">19375133</pub-id></mixed-citation></ref><ref id="pone.0077823-Svanberg1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Svanberg</surname><given-names>E</given-names></name>, <name><surname>Frost</surname><given-names>RA</given-names></name>, <name><surname>Lang</surname><given-names>CH</given-names></name>, <name><surname>Isgaard</surname><given-names>J</given-names></name>, <name><surname>Jefferson</surname><given-names>LS</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>IGF-I/IGFBP-3 binary complex modulates sepsis-induced inhibition of protein synthesis in skeletal muscle</article-title>. <source>Am J Physiol Endocrinol Metab</source>
<volume>279</volume>: <fpage>E1145</fpage>–<lpage>1158</lpage>.<pub-id pub-id-type="pmid">11052971</pub-id></mixed-citation></ref><ref id="pone.0077823-Belizon1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Belizon</surname><given-names>A</given-names></name>, <name><surname>Kirman</surname><given-names>I</given-names></name>, <name><surname>Balik</surname><given-names>E</given-names></name>, <name><surname>Karten</surname><given-names>M</given-names></name>, <name><surname>Jain</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Major surgical trauma induces proteolysis of insulin-like growth factor binding protein-3 in transgenic mice and is associated with a rapid increase in circulating levels of matrix metalloproteinase-9</article-title>. <source>Surg Endosc</source>
<volume>21</volume>: <fpage>653</fpage>–<lpage>658</lpage>.<pub-id pub-id-type="pmid">17165116</pub-id></mixed-citation></ref></ref-list></back></article>